var title_f7_19_7472="Peripheral lung abscesses CT";
var content_f7_19_7472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung abscesses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT in a patient with hematogenous lung infection due to Staphylococcus aureus. There are multiple peripheral abscesses in both lung fields. The infection arose from a contaminated Hickman catheter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jay Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7472=[""].join("\n");
var outline_f7_19_7472=null;
var title_f7_19_7473="Angulated sleeve gastrectomy";
var content_f7_19_7473=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angulated sleeve gastrectomy (corkscrew sleeve)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAaUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ZkdhI+Gbqe9M8x/77fnRL/rH+pptADvMf++350eY/wDfb86bRQA7zH/vt+dHmP8A32/Om0UAO8x/77fnR5j/AN9vzptFADvMf++350eY/wDfb86bRQA7zH/vt+dHmP8A32/Om0UAO8x/77fnR5j/AN9vzptFADvMf++350eY/wDfb86bRQA7zH/vt+dHmP8A32/Om0UAO8x/77fnR5j/AN9vzptFADvMf++350eY/wDfb86bRQA7zH/vt+dHmP8A32/Om0ooAXzH/vt+dSxSPGwYsxx2zTFIVgcZApdy45B6+vNAFiTczbt7g4zgnirduJPmZnPHHJqiso2g8k9B7Vbhlzkv8g/Mn8KAOg0qZ0BKseg5J6mvQrI+UsDZIZsHmvLdH1EJdCMW4I4zvb+deoaW5vp0Y8RL+GcelAHqfhqQtaISx4PQVrysSx5Nc94akzEAAOOfpXQy8txQBRliWQNHLHHKh6rKgZfyPFclrngPwzqbN5ulJbvjPmWjmE/XA+X9K7LIBOaqHndnmgDxbX/hD5RZtH1lsAcJdpj/AMeXP8q4bW/BHibRoXnutOuJLVetxbnzY8epZc4/HFfS1+m6PP51laXqk2l3mAzBc4yD2/woA+V/Mf8Avt+dHmP/AH2/OvrvWfBXhTxfbma90uGO6Yc3Fp+5lB/D5T+INeSeK/gZqlksk/hy8j1OEZIt5B5U+PQc7WP0IPtQB4/5j/32/OjzH/vt+dT6jYXem3T2uoWs9rcp96KaMow/A81WoAd5j/32/OjzH/vt+dNooAd5j/32/OjzH/vt+dNooAd5j/32/OjzH/vt+dNooAd5j/32/OjzH/vt+dNooAd5j/32/OjzH/vt+dNooAd5j/32/OjzH/vt+dNooAt2bt8/zN270U2z/j/CigCCX/WP9TTadL/rH+pptABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRS0AKcbRjOe9AQlcjoKQ05GwcH7p60ALF97GM+lOKBD8xGKiz6UHnrQA8vgYQbR+tMyc5zzSUUAaOkMZr23hY4BcEkfnzXsvh9FEQKknIxzXkXhSPzNZj4+6pP8AT+tevaQwjIUHCigD0HwxwGz0rpicDP4iuV8LTxl3UDJ966mRgQMUAV2GAeearY6/WrDnOeBUBIz0/WgCCZSRg+lc9fRxiQkrz3xXTybcdOlYOrKEckjg8igCnba3JpWyQt+73AH2+td9puoQalarNbsCcfMvpXk+uKDZMNwHIrI0HxRdaFfId5MPTnpj0oA9l8Q6FpniGz+y63Yw30QGFMgw8f8AuuOV/A14l40+CNzbrJdeErhryMcmyuCBMP8AdbhX+nB+te5aNqltrNktxaMM4+dO6mrTL9aAPiG9tbixupba9glt7mJtrxSqVZT6EHkVBX2N4s8KaP4qtPI1u0EkijEdzH8s0X0buPY5HtXz14++F2reF1lvbX/iY6Opz9oiXDxD/pon8P1GR79qAPPqKKKACiiigAooooAKKKKACiiigCzZ/wAf4UUWf8f4UUAQS/6x/qabTpf9Y/1NNoAKKKKACiiigAooooAKUDJwOtPgheeTZGMn+Vai2awDb1Y/xY6/SgDMERHB64phHoKv3EfZVwM/WligEhb5ffNAFDYcZpuK0pIwXKgcjqaY0CkgcigCgQQaStBbNnl27eB1oezQEtuyM4GKAKFKFJHFX2tWYAhdq4qaCIRxsAmdwoAymUr1ptXrmH5vbFVthAbPQUARUUpBGCe9JQAtJRRQAUUUUAFFFFAG74RYLqEn94xkD8xXpelFti5Jx29a848Gxb793OAqrzmvUIF8rYQvytyMetAHWeFJCL4LkYYdK75jwn0rzbw84j1KBwT97FeiFhlRmgBHACj396gkHOQO9TyD9OlRnGeOlAEJ7jOKydWiLwsVHzJz68elazjDc5HvVa4UFieeRQB5/q+82koGDkiuY1C28yInAyBjPr+Nd5qloqXLxnIUjIOOlcnrUcWGijOG6YoAyfCfi648MakgLsYCcAnp9D7V9BaBrFnr+nJd2Dgj+NM8qf8ACvlbWYWZPLz85OM9cVf+H3iu+8M6tGqSk2/3Tu6EehoA+qHXJ7UwqQQV47fUf4VDoeq2ut6el1aMpB+8vdTV5kGDxQB4/wDET4R2esebf+GxFYakRua1+7BOf9n/AJ5t/wCOn2618/ajY3WmX01nqFvLbXULbZIpV2sp9xX226dfSuW8ceDNL8YWPlajH5d2i7YL2Nf3kXoD/eX/AGT+GKAPkSiug8Z+FNT8JaobPU4vkfJguE5jnUHG5T/MdR3rn6ACiiigAooooAKKKKALNn/H+FFFn/H+FFAEEv8ArH+pptOl/wBY/wBTTaACiiigAooooAKt6bYy38/lxcAcs56KKdpenzajceXEMKOXc9FHqa7a0tIbaFbe3wqL1JHLH1NAGcmnx2sAjiTlfvN3Y+9RyW+SDt7VsAZbHrxg04qR0H50Ac89q5cDaQM1cFie+QehwK1Y0CtnGSeKR8k57DtQBjfYsnagA45J606PT40Bdzu9q1Cp38DAp0luSMMCoz+JoAyPILSgIM9yf8aZ9jVZOB5nOR6VtIm1NoHBqtIgJJPT1FAGTcRMx4XLZ6dqDAEQFckn1rUEH1znpRPGFBx06YHagDAlj3MxIAB7elQtDkYHTGa15E4+VQM96r/Z8kZ5IP6UAYckDliQuBmmTxeVt55NasyMWOOOcY/z3qlfRkuMdDQBRopxXBxRJt3fJnHvQA2iiigApRyaSpoImk+6OaAOs8F2+Mv6dR616NYqZLR8jlSCCK4zwbb7LeUgcgqK7+xhxbMCfmYbvegCWyxHLGyngHNeh27iWGNweoBrg7aIBt7D6V0+g3QDNbtnGAyk+vpQBuv1x7VECf1pw5bIpAMHnOKAElGWBB5xVeVCcgYJq2VyentUDghlIGcUAYmt24ktjIB86qR+leX3Msk9w5A2vnn27V7JeR74X2gbsdPWvLNdt1tb6RkXarHIB7UAcxc2u+V3wMYIJHfNYN1arAp6MfSunWUBJDjNZs4E/JhQhueRz+dAFjwB4xu/DepoJJWNux2gE8Y9DX0xo2qWus2CXVo4II+ZM8qa+T3sy5O2HgDkHnNdP4E8WXnhrUhHIzeTkLhzwQexoA+k3XrUDrnPH4Umkana6vZLc2bhlI+Zc/dNTuozQBh+INEsNe0uXT9Xt1ntZOe26Nv7yH+Fh6/gcivmH4ieBb/wZfoJW+06bOT9nu1XAb1Vh/Cw9PxGa+tHT07daztY0yz1bTbjT9TgW4sp12yRt+hB7MOx7UAfFlFdl8SPAt54N1IDLXGlTsfs11jGf9h/Rx6d+orjaACiiigAooooAs2f8f4UUWf8f4UUAQS/6x/qabTpf9Y/1NNoAKKKKACrWn2ct9crDDjJ5LHoo9ahgheeZIolLO5wAK7XTLJbC28lMM55d/7x9PpQBas7eO0tlgtgAg5JPVj6mp41yff605ABEeOpqQAcZBz1PFADNmME9c5HtSgZ5bjHc1KFDDr0okUGMqMhc0AQ4z04zS+UXOBk89qmijLNz09RVpIlHCjp1oAr29uFbcSGI5+lJOhJJOD2q4VAyCSB64qKRefYd/WgCgBjcQDjHp1qLZ14H0q8IiQc8D+lHkKfU5oAqLDhQzYHtnr71DcxhlBzjt9fer1xtA4PHfFQFdylcYXuKAM6aEH7vUcVA6bOikk9DWgVycMoOf1pphBwOlAGXdw8dACRVG6gygIxu+lbM8ZLdD171C0IaFwQd/c9qAOdaEZJJqvJBxlcf41sywtg8Aj19aqTQFYvmB+boMUAZske08VHg5xVuaI7xt5x3qaOFPL+VSZc59aAKawkEZHJ9e1alpB5MW5vrn2psUao2JMMxPT0qyx2M6SDBGOKAO98GRoumK06k+a7MB3IHeupN0ZWUJGI0yMAdQKyPD1ns0223LgmMYA9K21twBkbVoAuWyMUYr1Hb1FWkRoX8xThh0xVWA7Hz5uCB2q0ZEdMNJk0AdNpt2t3bh1PzDhh6GruMjI71xdjfCyut5Pynhq6yGYSqrKQQRnjvQBYTGeelOaPK5449aRBnI7U7ICnIJ5oAz7zdFk4yO+OprmvE2lRXVs1xGAW2knHc119ygkQYAyRxjoa53Ui8MJ2ZxnDqfSgDx3UlaBSpGzGcE9/b61iXF3IPljbGDzx1rt/E2nKxe6tAAP40PauHuWhEbYcBu4Jxj2oArfaJgcGQk9arvqErEl/mXOM9/wpZZUMZCYL8dOlRwQmQk4OSO9AHb/Djx3Jol8iSuVichct0Psa+kNL1C31WyS6tWBVhyAc4PpXxybfCkHk133w68ZXPh+4jinkJtT8vzHp7H2oA+jmU/lUDr7Uul39vqtmtxaMGU4LDPK1M60AZGr6XZ6vp0+n6nbi4spxtkQ/oQezDqD2r5W+Ifg288G6z9luGE1pMC9rcgcSpnuOzDoR/Qivrpl4rD8V+HrHxPoc2l6mv7qT5klCgtC46Ovv2I7jigD43orW8UaDe+GtbudL1JNs8J4Ycq6nkMp7gismgAooooAs2f8AH+FFFn/H+FFAEEv+sf6mm06X/WP9TTaACiitLR7QTS+bIP3aHjPc0AauhWQto1lcf6RJ0z/AP8TW+oy3UVnQhtwb0Oa0YBnBPU0AWkQKoGeB0xT1XIxkEUID6c1Oi4AzjB96AExtH6U5IhgBuPapo4cHc3PP5VMygkbQCc0AR+WVOD0FOPyg4IweCakYEnqfTnoaVAS3Tr6UAMZeRnsKjdQOT36VO4GSRnrUUmCc45PegCEgEnuDxnrUcvyqB0PTPpUyqByRxUezJ4xk9aAK2zPXpigqOmODxVnZgD0prKAQecigCk0QBPHHrSvEEUAfUGrjxYfJIx6VFcISB047UAZzx/MOrHvUbQ4V/wCtaDx8ZX8KYUzCRgY6dKAMh4w3UZHfFRNatIjckRj863I7TJyRgenX86nW135OFC4zmgDkprMGIbRtA6DuagiQRShiPlH3ua6mS3+VlK/L71i6nEiKWyAQckf3aAM26XbIX4VeuT/nrUNmzXWp2yEELvB2k9RTL52lZCy7VA49Kt6BFnWLRVO4bqAPYdNOyBI25AUAVe+YgAH86gtowsQwOO5q0BhQelAEb5APzDipEBCAcc9T701U3Px9frS7cdO34UAQzbsc449+1aGgai9s/kucoTkA1nyg898darsDnqcjoaAPSLedJUDI2auK2QeM+1cFourlHEbttPYno1ddYX0c/GdsnpQBbn4VSBx2rD1J12tvHPTNbdwCU9ayr2LzF6gGgDhNdtHaOSS2Zd+OV7N7e1eM6tE0N/KpR4/mztPUV7H4sheEO0bsmOjKa811O6e9lVbqGOR14Eo+V/xoAwIP3jEng9/eta2UrG3OOOKgigRSpXnn5lPGKuxDbgbSdwOM8YoAjMbEgY4zmpGjBixkcc4FMEyrhWPNT7lKEqMAnqaAOq8B+NLnw/dpFKxe2+6CT29DX0HpeoW2rWSXFo4YHqvdTXyc67zxjmut8A+L7nQNTEMjEwHjk8fQ0AfRbJULL3703SdRt9VslubRgVI5XPKmrDjOetAHn/xV8Ep4w0PNqqjWbQFrVunmjqYiffqPQ/U18sSI8UjRyKySKSrKwwQR1BFfcLqcmvCPj/4KET/8JTpsWI5GCX6KPuufuy49G6H3+tAHiVFFFAFmz/j/AAoos/4/wooAgl/1j/U02nS/6x/qabQA+GNpZFRepNdTaRrHEsaD5FHHqay9GgwjyEfMw4+lbUIxjHFAFuFNwJB56mrcQyeARxxioougBHWrEQ5yaALUDn7o/GrkSZHI5HSq1umSpOfatFAMdAB6UAKqAYxx60vA47DinY5x0J9aO+e9ACBMnP8AnFOzjn+tIcA8HPsKa5GOpz16UANYd84FRKpY8dPXNTFeACCfr60oULgDPPfNAELjsB+VJtBH9alC8k55p20Efh3oArBVbjkccUSLsOOpPtVgrtPGcnqajK57HPv1FAEMq5O4nnFRuvzg5IqwwyTk/TNOWHIBY49sUAUxFvOAPxNTRwhUGOeOvpVhY+efyqXyhtB70AVo4+D2B71J5QRT3apguBgdfeo5pPLHHLnuaAM+9Aj2uc89u9cxqcfmyMWGMnOO1dLOpkPz5JNZWpQe4z6UAczPAWQ44xxz0Nafg+38zXoCOiAse9QTw4yOfXiug+H9r5mqXEmDhUxQB6NaqWjRg3BHSpnJ2gjJxUkKILdVAxjn1pjdfm5oAkgQBCzN+A7Ukvy55zTFJ+buKLrPDL1wAaAIpT1+tUZWIJIJ59+tSzSkbgv3j61SaQ5wTkmgAd+MA8CtLS9WeJgJ2yo4Vsc1juRjp9KbEc+9AHqGjX5uLYszZAPBPerE8YkBMeTxzXLaDdGGFYzg7iDj0rquVQMvU0AcF430s3FsfLR2bvg15df2UkR2yKqlfXrivoe8tlmi+ZeCOQfWuK1zw2LneFhTn+I9R70AePLApUqwOegKnj8asXLR2sBySxbH0H1rppfCt7EziNVxg4J6n0FZOr+FdWKq8FtJI54ITnAoA5eW93SHeucnqKtMg8keUzFie3SrkXhLWZDsXT7hicYcJ0q7d+Hb7SbWI3cTbXyMjnkUAYMcsqHBIIHYHmpPtUS/PKrI5PB65qS5RlZlVDx1z0qjPGGySxOOcDgfSgD0LwD40l0e8RfMDQsccnjHoa+gdJ1K11eyW4tHBUj5lzypr4skG0qcHH8q7H4e+Pr7w3exrJKz2pIXD88eh9qAPqtl55qnfWcF7Z3FpeRCW1uEaKWM/wAakYIpmga1aa9p6XliwIP30zyhq6+aAPjnx94Zn8JeJ7vS5iXiU+Zbyn/lrE33W+vY+4Nc7X1H8bfCf/CR+FGu7WMvqemBpYgvJeLrInvj7w+h9a+XKALNn/H+FFFn/H+FFAEEv+sf6mnQxmWQKPx+lNl/1j/U1e05dql8cngUAalmoUjHA6CtKHpgjB71Stjggk9R3rShIJGetAE0fGBV63G45PIHTnrVaFN546d8VqQQlVHAoAngXJHFXeD2/KoYxjBC+1SqDwAOKAHdBjHFDc9BxSngd+ajJLcZ4oAGOQAMZFCA9e1GACfQDFOGfwoAQLk57ilIxUgHA6DFKADgnp6UARheBk9aXbjrTwOCf0poXNAEZGQSeKTHyn1PpU20t05PrTvLA46Y60AQJHjqc96m2cY7kZqRYx1/yacFzz+P4UAQBNozjBpeduBnPpUjDniomOVIA+vNAEcj4OFyT3IqJ0LdfzxUwQngDmlK4PA5FAFCVAqkdz69qzr9Ogz14+tbMiA7iOfb0qhcR7hnAzmgDmbhM7hjA6ZFdd4At/KEoAy7jk1z9xEPMJI5PUV2PgqIq4bPB/lQB1MXKsMdagk4bt1qZR83YCghXnUA5IwTQBCnyuc/U5pGkLMdx9anlhIG44Ck9zVUr85OcAYoApTD5mxyelUrgbeOOfetLHmHIIPOKp3UeHPB+vWgCgW/DirNiodmVsY6k+tQPDkjOeDnirtivlswPTHPFAGnpjZkycDJxnOMV3FhILiIq33lAz6VwunxGWdEAyCefeu+06EQwLxjNACSEq3rURQdSKtzKC/PpSBVI6flQBnyQIx6cdalt7EtJ0A9sdPpV1I1J9AatwgLxgYFAFK+zb2rv0Cj06V5f8TbmRNMtWimbLyk8DGOK9W1J0SKTeBtxnmvE/iHqyX00dvHwYSRz9KAOGu5JbjHmyM+BgAnis6YbVOepNaEi4yQM+tU5QSp4wCPrQBmynLEkflxmqjjJ4rSeLdggHioPKweM5AoA6T4e+NbzwxqUf7wm3J2kN0x6H2r6k8P6zZ6/py3dk4PHzpnlD/hXxfPFgszZwK6z4e+NrzwzqCfvD5BIBB6Y9D7UAfWRXawK447HvXyb8XvC3/CLeMbiK3Qrp92PtNr6BGJyn/ATkfgK+pNA1m017TUu7NgQR86Z5U/4Vxvxv8ADP8AwkHgmae2jD32mE3UeByY8fvFHrwA2P8AZoA+YLP+P8KKLP8Aj/CigCJl3TEDqWrVt0Cqdv8ADjg1QhXM8jHsTWpCCQO4wKALluO2B179K0YgWPHfpVG3XCnpzxWrZRnAbOOOKAL1nEFwOSR1rViAAGBVG3GBxV2E4bHBPegCyqYHGKU8ckdsikBwoNDvu6nI6UANLbvoecU7HPBoVcDj9KeQQcUAGABTtvHfNJgHrUqgdD0NADegPApSMGlHp+vvTgC2AB07UARnj0FPRGZeuBT0jHVgDipAD+NADAgXIAoC4bgcVJgD6+1LjgDp7UAMC9KaehxwD6d6kbj15HemHkkgH60AROCc4PPfFMC89OOlS4IOcc/WlC+1AEO05PHPShh+FS7fpxSHjOMUAV5B1qiy7lxj5f61fnGFOOOPzqvEBwQc460AZU8GJBjpmuu8NIIrTzOQWUAD2rHa2ErZAG0Hmuhs/kh28Zz36YoAtq28nceAKgExEm7BBJ7Usz7UAzgnnioHY8c4zQBYluHLEk7sdjTGcOCQOB6VVdyTgc/SlicoGHJFADZCAfb0qFpTjnBFTzZYEgD8KoSj3OKAJg4LAkDH5Gpyu0lkIx6VnoTu3Hk1aMmYDtPzAfnQBo6PdbdRhJwATXex3SkDHTqQa8kS9+zyiQnODyK6TSfFVvdSGFUdWQDdv6keo9aAO9MoePJHI5FRLL06Vn2t2pAwQQeMZ5qyu2QkIwJ64oAsmUjjOCe1Kl+N/lKVZx1PcVWkxCoZz0rM04mK8nnuPlDHKEHqKANbVJQsJdidwB5rwPWiZ9UvZeXDSsQfavRvGnigRGSxtIy8hX55GOAoPYV5rKGGSSTnqaAMyUDG0jIFQvEWXjrV2SM7s5zj9TTVUY57UAZRiIwM4z+lNMBJGc4z1xWk6ZUnHNRtGcDg8+nb60AZNxbeaOW2Y5+tZrgfdcHPrit2SI+b82AO/rUM1vjcvXPvQBu/Djxpd+GNSjTzCbdjjDdMehr6f0TVbPXNPW6tdskbDEkR7ZHKn2IzXxlcRFQQFP4V2Pw18b3nhzUUR5GaA/KVboR6GgDM8c+Hm8L+MdU0vkwJIHgYjG6JvmQ/kcfhRXt3jnwdH8Sl0zWNEnhhnjiaG48w4JAOUH4Zb9KKAPnKHG8+m4k/nWnAAUGehrNh6k+jEfrWnbDMK49aANC0XecnGAOcVs2aAA7s9sD/AAqhZpgYHXqeK0oPbg0AWo+O/wCNTocVWU8DtjrUm/sOtAFoSE8e3ODUycelVIj9ferK8DvjFAE2cVIvLY7UxRkj6dalAAOMZNADwvNLt4AxSjn6CpUXnk8UAMCE9PxPvUiqBx+dShcjJ4JpQv8A+ugCILjAP4U7acY46c1Js9BxSdAB3xQAnAH6Uxj+fTHpSluw/WgKSOe1ADCPXik24zgZHtUgH/66XHpQBHtzwaCMgZ6VJ0HTnrTT/PmgCLBycio2I2k9alcjv9KrSsSG9KAI3O4HGMf0ptumSQp4Pej72MY/CrVqgC+2evrQBLDGAwBA9hWlGoWPGflHNVI87kPGc8CrVw4zsToOtAELtvJZuvao2HAxUud2c4yfWmnJ6Y/KgCDaS3cU+NG2PwcjvV6OLC443GoSSGlXJ4xigCsVwo656YqrMhPBBHfFT7zuJOcfWo5G54J/CgCoyH64qeyTzZgr8BxtzUW75xk5zxmrEAPmqVOcECgDHv7d43dSuCpxWRK8lvLvjOCRtzXY63AVd8rwT16VjNpz3kbLGh3Hj3oA0vC/iKWeZLWaMKFXBlJ5r0TTrpANo+bI6jrXC+HPD0kQDSId7c13UFqttFgABiOST0oAdeylwASNmc1zVy7S3CzIS0fmHCjoBWhq12IbR2chVx39K5uyvcaVbvKxVHDbiRj1oA5zW7gXOqXUgIK7toOeoFZ7AgYboeKYZoxK5jIMRY7fpUrEFfY9hQBRmQnle3UVGoyuSehq4ygHuRUTxhslcZz0oAr7VIB5pAEB6ZHSncj72c+lKVB7j1oAhYKSeB9aqyRjqeR61cZMH9KhnVVAHUnjBoAy541YdM/SqscC+YqnJz+GOavXKMW3dCBwAeD9agtwTNGGHzD16UAe+/DPzY9EIRmAyO+PWipPhsf+JKfqPf1ooA+bIer8/wARrY09dyhjnaDx9ayIcfvP941vacu21QHuSaANW3yEHPJq3H7delU4Dk8+mOnarfmiKPIBLE/KP60ATyPhiqDn+Qp0Q6E5zVWL5uSec1biHYfUUAWo+nNWowMjFVo+wyfyq2nA56UASKcH6d6nUZAxk1XTg571ahGDkg/WgCSMHOTnP8qlAw3FNA7gfjUi8Y5oAevrQPXFNBwD60jNwc0ASdiKZnPQUzdlvXHal78c5oAePu9OKdTeMZH/AOulJ4J5oAXj2pT+GetMyepo3emc0AKeh5xUbsBnHJFB9aY3vySaAK8hy3XmoHALHHWrLrkkAde1RmPDY4yaAGwRDPXnvVyFQFGM1XTLEAHjrmrW4ICTyO2e9ADpCEQf3j0p4yT1B7ZquhMkg/Wpyce5yTmgB7Yyf6VatVXIyo6jjrVRfmAIBJ6Yq5ENhUN94nJHpQA+T5ZfUZqnJjfIT3qw7EvknJzVHUciZwOx5AoArOwBOWx9O9Vnc7uDkZx1obn61C/X1Pb0oARX3McdQDgGtWyXdMJHwi8ZOetYoXkv/EeM+tatiwZMfxLz9aAL+qus7MByO2K0/D1mplBCjJ/QVy6ytvAGW5yATXeeG02qWPUKDj60AbUcaonygVDOFHUZq0BlcjrUE4HXFAHC+N1lmWOGHJJYEr0z9a4fU2ZbydGdnRDjYGIA9q9J1Fd11JMw5Xhff2rj9Q0Rmka6tzlmJLK3P40AcmF8rgL8hGdtTIM4ZDx0qe+tZYSVlRkwOCP4qpjKnj05FADndl/Hp7UCTt1I7ClbDqNvPNQtEGz/AD7mgBzlXGD1FQqdhw3Bz17Um2QNx0HtRvIXDoev4UAJuOfb+VMlAck7c4/z+dNwWyyncB271BLclfl2fSgCB4x5xYKevBqKNlW5XK855PpSTTsGwxPPOKiSRHnRWyf60AfQ3w1GdGdlJAJH9aKZ8NGV9DPIOCOlFAHzbAMs47lv610VqvyYHOAMZNYFqAZR/vEmt+3OU7Z460AadsM8evemM/mys3booPYUzzNkBPc/KBTYPm5AxigC9ETjA/U1biOTx0/z1qnHz061bi5xzigC5FwDzmri/dAHT0qlGener0a7Rk8MeaAJUBA5/WrKY+vvVdPvdPxqdOMDn86AJ1ODgH8CeKdwOV+tQlwBnNKGJPpQBIT19RSE5PPOaaOeadjtQAZz1JPv6U8HIqPHT9aePT17UAO4x1pM+xP170i88Z6c0E4bFAC855oGaaD09M04HH0NAAxA9aYAW/8A1U4rkc8A/rTsDHsKAIyg29Mn1qORflOWyeuKsY46VBLjJNAEQwvUkd+tBcu3JxjoDUJZnfjPHrU0C7pBnsaALsSeWmOjHqakWIk5PGaVBwTkcetIzHacUAWoERFO3G7rnqaTqxbPy45xTLYn+7kHqBU78RsB0xQBXDbXBzgA5FRzBXcn3o3YIz1pjtgnAzigCpNDknbxz0qk8ZB5BArT3ZH170iBcgEjB9aAKMNuznJBA659quiDEDsnUHBzWgkSlCQ2eOcDpVeWfbAyxqMk88UAc5KzhSDwOehrvPCV1K9vEH5YLtyfSuLuZVCNvwB0z3NaPhvXks7lILpwYD91uhU/4UAeng5we1I7ADDDNQwzI6gqRtIzkd6ZfOUjLKT7GgCje20UjY28nmqX2dScbBjtgVNHKznapxn1rStYlA+bGR3xQBgXGjw3imOWLcCORjI9q43xT4X/ALOhae3yUHVT/D+NetrDz8g/KqupWIntnSQEgrggUAeAFthOMkelCyBgeh+narniCyOmalPa5JCcq3sax3OPu9aALYbJGaXAYkA84781VimLcPge/arSsQVKg9OaAEaBVU87Sw6is+8iZi5VRuAzgHg1oyBZBgfezkelV5GVlKgEY4YGgDn7h2D7SjDPXNVg7GVE5PPUdRW/PEskQDKSMduorINttuFKtxmgD6B+Fx26EVUlsED+dFJ8MwTorDkYI7fWigD54sv9cxz0J/nW5adz+VYljw0hH96tm1YADIzyPwoAs3Lf6pfq39Klt29cYqrIN03OAAAOat2xVQOp+vSgC7CAeXOBVyPHG0H8e9U0O49Rgdqv2iDbuI+g96ALluuACRk/yq0p5Bxk9zUEfB56gVMpweRigCdO3tUgYAY4z2FVt3O0dcU9KAJgT+PapAc4qMEDjNPQ5x3FAEoPFP6jrTE7nnNJ1A9PSgB5Y5xQevvn1pvbqM0oJ6nFADu2eOeDSKef60AHpj3pVXn0FACqpPTv0qRV5Gef6UoweOnrS4x1oAQ9eOaTbnknp0pygds/WmswAHTFADGOM+lVZuWHYenoasnnrz2qNlAyWx+NAEESdT2qeIFWBHX0pAV2/eB/Gp4gMcHPOM0ASAdckZprnjj1obIGBx/SkYnjgH8aADccdTinLKyjO4n9ahYkYHb+dIDznGM/pQBbjbeCc5HXio5snGcUy1cjeuO2aR2JByMAc/hQBEw55/SkGdxwOetPZi2CMcU2LpyQM8emKALlm5DEAjJBqGZMMexPWmpIkc6fOPlP6U7UnTzGBbvxu96AOW1F99wwB+QVTK5b/Zq5OAbiTnnd0qDufSgDY0DxJdaTIscjtLan+AnO36V6LpupRarab0J2H16ivGpiAcjGB713nhqQwWNtJHjlfwPtQB2tvZxqAQDu6gmtO2hGM4AFZ+k3kc4Kk4cDpmtiE4AHrQBIFAGBUdwoZCCOMU9nx6DnioZ5F2nJ7dKAPDfiWixa8CpBzH0HXrXFFgecjA5/Ctzxjdvd+Ib5nJKrIyL7AGufuZFSIu3IHSgCXdhc8Y7VYgfYvQsv8q503DStzwKvWMzDrnHSgDaZwcFMHA4Heq0s5APy4b19ajaTcdytkjsabLIu0mQbffPWgBzFioIJBPHNUpj+9WQZ4xTncgE5JJ/M1Alxtli8wjrzQB758M5EOjPjd1X+tFO+GbL/AGK23leMfrRQB862hOWH+0cVpQnAPpxzWTb/AOsbB6E1rQDjoOBQBO5Jnf1BwKtwjH09qp5/fOD65FXbcF3AHU0AaNqm5gP4V681qrjBPTjFUbdSihRjjr9atqc49KALKEdc8+9Sb9o+vPrUOcLnt70Lyc55IoAsrnPJ5NSr19Tiooxj/PWpV49PegCVe3oKkB/H+lRj2PSng8dsD1oAeP1p5HI9KjWn9h1/+vQAuQfpRnr60dPWnqmPmIoAWMZ57dBUw7E/WkjXnpUgAGQORQAigDOajlkVME9vSnu5QFief5Vh6rqK26ktgt2oA0JtQihX5sewzWZda9CvTABPXNcNrmvkSOFbdIeOtcxcXk87Zdz+BoA9VXWI7klY5cnuM043JyBk89s9K848O3LpfIM8Hg+9dzG289c8d6ANOOU7utaOnzYcgHB6/WsWNuePpVm3lKXEZHQsBj60AdIMPx3HPNIy9vbv61XV9sxwTw2Ktsc9e4/OgCsVJY84p6xkjgAUOCenpxVsR7I1BHI5oAqwL87c9qGXAz+PNTEBWYkcDqaz7+cKpUHAboff0oAhublUBCfXNZL3JZ/vHNMubnJIYgA9PrWfJKQ3fPb6+1AG68hkjilD4ydhXPerV66z2Svkq4ym4+orK0s/aYSgA3CQHjsav3Efl2gQMCxy23P60AcpdTslwxU9ecZotNRWQhHI3HgMf5VWvQROcHryCe1Zvz+cSvDA9OxNAHRyLk8ntgir2matNYSqqktFnBjPQfSqEIZ1BbPQdaXaMg8dOaAPTvDt3Hd4ljJwfSujiunF1hJCQOOK41Iho+mrcKfLkkTKKOvT0rN0vxLdKrPcKGCclh39BQB6k16MkE1heLNfTTdKnlQgy4wB7npXFyeMwqN+5kLZ4wRXK69q82pugOVjXJCk5yaAMe4d3lZ35ZiWJPcmqN5E0tvIiAFscVakUk5AJPpQQIkPduo9aAMGGN87WjfcD6VrRW4RRvB688UgueuVHXjFWlPmpwefftQBATtboAo7d6r3LAghgNn8qtmE4yGLHoc1UuCY0bg4HWgChNIEc54YHG49KiRwsqOWHXk9qW5cOrZyO5BFUC53hsnI6UAfSHwvmV9DYoVIyvf60VnfCl92gsR0yPY96KAPC7f77f7xrUhbj8KyImAlbJ4yf51pwyLjlce4oAsA5mzz82Dg1qWA4ZzzjgVlqNuDnORitW1G1Avb2oA0o8Yx3/WrkWABu/OqEeSRjoatq/IAOAKALBbI9vepE7D+VV1+9gj6VMhoAspnGAPxqZOw71CnuKmAzigCUdO+OlP/AM80z6ZzTlGP60ASqaeM8dz71GBzjFTKAPc0AORcDJPI6VIBnqeaZ3z608HHHagCUDOMDinbgoLZGfeos46d6ilkwDngKKAKurXqW0LOxA9K8u1/WjJIyxksx/StDxnrvmyNDC3TgD29a4kkk5JyaABmLMSxyT1NJRRQBqaBGWuwfyru4V2r+HJrlvC9scmZhxggZrqrddxAHAHbFAFiLH3QOtWLVC1wrY3BecVCFLH+WK1LeLy0H94jk0AWFk/eZHqfzrUiUvGvGSfSspA3GOSeoNdBbDbZgDqAATQA2CMK434J44qWRC8xCDJJqFOZE5G7vXUaPZJHlnAMh5Oe1AGKNMYlt0ZJ4OKyL/w9eTwu0CscNwh6/hXpXkqTkgZ9aUKFyBQB5K/gzUpIVeONS7LkpnlT61g33gzWxKSsE3Fe8jrx/KlU9OfyoA8Y0vw1q0U6tLazBWG1gB0461ffw1rMrEGzkIPFeuAkYAJ/OlHqM0AeI3ngjWZJABYuw9cinWnwy1OUAzNHAM5O85P4V7YQCPXNIyg/WgDyOTwbcW/yJEZMDG/cMkfSm2nhfEqvdxvFApyS38WO2K9PuEOD2PqKytTt55IwYyGHv2oA5LXAb2XzT8kKLsX0A9q5S9ZUQCJlEScYH611Pi2UafaI07K854WMHv8A4V5zq2pbbKdhguSTx0GfSgB5uVeQKgB7c8VT1K6ELFI8M/qK5xNSkZt5wvrzVSe4eSQnJzn1oA3obwqS7sWOMYqe3v4pOJUy+cA+1YUEu6Jl7ipLZ3U8k4x0xQBuPbRP+8jHJNESASEggD+dRaecuyK2QR39auCMAN3oAR0K9PzHasyb0IbGc896vNI0YbzBgDjNUZ7hTkDOByQe9AGbesGQlCBzjpjHtWb3rRlnRjh1Iz2J4rPK8gDkmgD3r4TsDoDYbByM5P1oqL4TEjQXB5IIBz+NFAHiCsRM49zWjb8kY/nWXnE7c9zV23PT1oA0rd/3gHp3xWvaHBznmsK0zvB9617dh9PegDSVvTjParEfOM9OtUIW/nV6M/nQBOD8wBxkc81aiHAzn6darIB1yKtRDOOxoAsoOP51MvTioUPGe3f3qVeOc0ASjr1p4PORTAcnjtUqLgk0APUlBx96lBP403hjRuGDjB57UASg8cU5WOBx0qEH1wakX07EZ4oAkUevNc34x1VdN05trDzJBgCt25mEUZZmCqBkk9q8m8UXz6nevISdinCKew9TQBz80jTStJIcsxyTTKUjBINJQAVYsofPuFTtnmooo2lkVI1LMeABXb+GtAlYL5cfmN1Y4oAnsYRDGiovHoK1bdWUnIxnvitGPTzakLLHh+vI6ipvKIwwXAJxmgCtbBAQepNXVI6nuackAKDK4zzxSmHHQnmgCa3H7xeflHXNbsDLnae4rDt1Knk/KOeanN8qDgAsD270Ab9hAHvIwQODnHsK622TaoPAJ5+lcJ4f1Bp9Wt1XqTgg+ld9u54oAkB9fy9aCSev1pAeRx+VITj6UALnH0pV/DimdzSgigCQHH405W4/yaizTWYgEjAoAnBpC9U/tKgYzxWfq+vWOmR7rqdELcqgOWb6AUAaVxMFycc4rj/EviiOxgdYQks46LnvXN694sutQYrbFra29f4m+vpXD3bnbIMs3UhyeWzQAzVdbe+nlluZMzBup6D2+lZE4SeAeZliecetZ91Z3CykqrNubPFXELKwVweRg49aAIJrKJ4SIsDmqDWbRvgnpzW5boTuz8oORS/ZgwLMm72J4oAxY4yrcYOfXpVxbc53Y+b0zWnHaRyvkRgbTxirv2dYwMDk9vegCnZW5Qb3PzHoOmKsN8rheAPpUqQqHG89Og7A0PjqcjJPGe9AFW8XcpKjcT29qw7qIM22MgFupzXQSfLgnORzgVj6lAQSyjIPP40AY00YBxk59KhFTSyOSdxwfp1qEcmgD3z4XkNojHv8v9aKh+FDBdCkV2wQwH6GigDw3jz2zk/MeBVyFtqkKACRgmqTHEr8c5NW4egwaANG0ZQCeSa07fn8cVkJkNgVp2pJA65oA0YOhGcVdiyV/wAapQAdf5+tW0IxwRQBbTPb86sx4wBgmqsfBGKspz2oAtR8r+HHFSr1/pUCHgHv25qRTx0A9qALCHB559al3N0qsDnpTgxIxzQBOW4O0j60g46/pTVIJqQD14xQAqnnv9TVhFLFcDLE4A9+1RL3z1q1p7AX1upI5cAn8aAOtTwZZXFqq3ZaQkDfzgGs65+FuhzSbkEsfsDkV30f3F/ClP4igDzO4+EGhPGArShx/Eeawbj4HwPO7Q6kUjPRSOn417Tnt1ppoA8isfhDFYfPHOrv/eY84rds/Bhs8BXTIHGDXdznC96pTyEA4oA5ibQHkYKzROy/d3549s1Uu9FmicgRRlQcrtP866CZ5AwOehqrLdhGyx3H3oA55tLuE6wP9KbLZyIv72FlHqRWvLqm04Qb39+lZ1zfz3ClZJPlP8I6GgDPkMe3aOMcVnyOATxmrbjCk1RuF6mgCzolyYNVt5F69K9NiuUaNHLAZryG3LrOrqTwc5rr9CvJbp1h/iyD9BQB3SnI+WlPbvTYl2ooPtT+hoAac9qT6U7j6Cqt7crBEWY496AHzSCJdzdKzNQ1WK3gZpJEix1LGsHW9ZYj9yW6ZIFcpqcBuT59y5O0fdDdKALmseKJ3laOxO4Z/wBY3T8q5a5aR5vNndppWOSWP3alncgkADaD3FQElvvEnjpQBXaSRzsPGegzSpGWzxuwMc1ajRSMccdKcm1TjPJ9qAKMtoWAIwrdhUJ0pJPmLYkPoe9ap5H3qUAIAT1zigCgmmFUwzA9xxRJppbCkgJ149a0mbbyByfzqF5CynJI9QKAKqWqRqACc+neh4cEMe3NPDneW3fTIpkkpLk5OPSgCq5YMxUZGMc1HJu2MMfTNWyRgEY/wqrcMAeVPHbtQBBKwQASMBx6dqqXGV53AgdjViU4I+UlW4PtVWVV2sATtHYmgDJvkVmP97rWex+fpjFXbwjeQD7ZqgetAHunwuYLoknOMkfj1oqD4Wt/xJHwO69efWigDxV/9c31NXIBnnHAqmx/fN9TV2L7ooAtRn5hwSa0rU55B71mR5JycVp2RBAPf0oA0o884x9asqeRjiqcTdPbsKto3rkUAW0PIq2vAxxVOPI6Vbj56GgCdTxjipM8AD9aiHAFSD1xQBMpzjngVIOuf5VEvTipQeRQBInXipP/ANeTUanpxzS5I5J4HWgB7OFB+bjuaqLemO5ilTkRsGA+lQXNwz/Kvyr/ADot1QglzznpQB7hYXKXNpFNG2VdQwNWC2Aea8u0DxM2igQXAMlnn7o6p9Pau607W7HUo1eyuEkz/CDyPqKANZjx1phbv1qLzQc85FML+9AD5m496y72YopAHNWLicAGuY1bVCMpGRv9+goAlubg5Jz82OKy5DJLLubl+u30q/ptu08AmclsjOarvA7XEjBDuHJxQBAQDGRgHB6kdKWK1aTJGMfWtaXTEuVVy2x+Oex+tWbfSiiAeYG96AOVntGAIx1NUpLVz1A/Dk13EmmIeTtP1qA6GjKRubruwB/WgDkU09iNqrliOgrofDdn9iMsznc54wKvLYwxkA/M3ov9TTzcRwIQyqNuOAKANqKZmUHGPapgxxxWJBq0RYBuvar6X0JGQefSgCS4uBGfU1l6w0c1nKxPzAcexq4UEx3HjAzx2rHuFLXEiuchhQBzwj/4l756g9+1ZkyPMRuwFAwWx1reu7cJHMV+7tzxWG8yyKEAwvXg96AMK8ULNhM7SOM96qrjHXBq7ej96yN1XtVFgSfl6ZoAUvsxnrSo/wB3jPPU81E7gswwSV6kUqA4HPDeooAd5jK2D2zU4wM5ye9QNu5BPbikR2TY2ep6UAWGdmyu3p3pjAEMDzntTTcDn27jpUTygFguQTz9aAGOpTp0z61UZyGyHxt5OP5VceTK7uABWaxcvlU2+hNADkZsnH3R60sxyDlgR35/lUEgY529CfyqMyrGAG5IGKAIJnCyOTwO3oarNMdm5gMngAd6sNJHIzlB8x9RVO53ZxQBQuGOTmqZ61amyaqnrQB7N8LH/wCJJJnrkdvrRUPwzl3aPISQOV4HHY0UAeRP/rm+pq3CRgc1Tk/1rfU1NCwyKAL8HJ71qWhAHHBrMtuhzxmr8DccdKANGI8d/wDCrUJ4B6/WqMZGKuw9P6GgC9H1Gc+9XEBA4yM+lU4ug9hVuPpx0+lAEucLkVIp6VC546/WpEIxQBZX5etPzTEPYGmyONuAD9cUAOM4BwBnFShg6hemarpCchuatW6oDyOaAIHsyp3dQRTHAjiyOvT1rTdlVM56dcVi6jvZwYnwAckZ60AUbu6Z8oQRjjIqbQrKcb5S7RvuwGRsGrdpYebHmXv0rZEKW9tuCjaoyMUATW2vajGQkdwWVTj5+ScVqweIr0rh1jPv0rltNIkeTIPXmtUKcDaRxQBfudWuZ1K5VB7VQX5lz1I/Wjbjjr2qRFxjIzQBueHLyNV+zSkKScoSevtXQRJh8kZFcKEwcHJOeo7V1Oi6iJYRFckCZRgEn7woA2vKj68c0vlKvSmh0HcVHLcwopLSKB6ZoAeUUHikKlup4/Q1nPrNsrfxH04pjaxkHy4vYEnigC7cBIkJYhRjNc/Le26F/LiMhJ5ZjjNJPPPdEtK2UAOQOBWYxGGU9OtAFs6layMPMtio7lSOK1LQWzoJI5t0ZrkJQck1H5joDiRkyM4B4xQB6At3AkTKJFAx1z1rnpL9Zr1nj5AGBjv7isFFLlSWJPB5PWr1uuS6YzkHFACXl2+H2cg9e4rKVcOMgA4xjHSrUg2MRzkGqTcnJIX1b0oAZfRq0okbBY8cVkzMI5DgLtzgYHNaU8gYlY84Axz3rLuVZ8qoG786AK9y5j24GVJ57UqsMZAIIIz70+YEovAJHaopg2QUJ57UAOJLN8vHJ6fpSjHRsYz+Zp0cZVAzkEj170BlZd2M+gHGaAIJ4uCyKcdxUAVxjIGMdc1pMMRsBkcVQLhiR/EPwoAZJ6e/QVDJEASQvOKsmPeAwyD9etMG/kE44I6UAZt+HQDBA3DtWXcgqvGefU10FzHthUkliDjJrHuELZOQfSgDOQyo26PgZ79KvMonTcBg4zj0rPkldHKqwIHWtCxcSQk4wcYxQBlXsZU5ByO9Uq1tRUA+/pWSetAHY6R4in0fTLeGz273G59wzx0H9aK5e2YsWJ7AAUUAV5f9Y/1NOiOGFNl/1j/U0gODkUAatu3cVow5x1rItXGBWrbEZoAvxnIA7ehFXYScDGce9Uoug5BNXogDQBch65wCKtowA9KpwjOPWlnlOMLwO/vQBYnuVVCFxn1p1pcGRQcce9ZpJdsfpV/ToznH40AaqA+4qVEXjimx8cDpUseCRQBNEmBjrSFRgnAzTlJ9qQN1zwM80AQzOGjyevSoYYAedgAznjvV1QrZ+X3p8cYyD2oAkhhG1QB24q3qCKLfySM4wT6CltWXzYh05qGa4Vrlz1BJHPpQBnRqYgyqigVYtpiflcUkrRFtuOevNPiMZbgg+9AEzjG0596mhyUJYdOPxpGTK8c1JApVcEcGgB8QDY7YqfYDTE2qcY6inbjjtQBKS/Te2OnWpI1VTkt16571UMwTlv51G+oqrhWUjPT2oA1mETLyR7VGGHIGAO1U4rqMjIbP40qSK5+V+vWgCSdvkIUjnrVIrkEYyRVtxx6Zqu3HI6k9aAITDlSzMqgHqev5VBlE6R7vd/8ACp3bBwefalXDDkYNAEghE0fm53EcZAxj2qGOY20u5Vy49auWzhVwQQDxtNR3sKmQ7cg9qAM24JMhbqc1nXihFyWAGc81pXrqgJxjFcZq2pNOxCKAucD0xQBde4L5MbDHQnNQySxRkM8igjkkHNczeXbQg7n57YrHfUZXbaAMe9AHdNd2zAfMMHpg0Ge2CBvMU1wbXjoVO7C/XrUtrehZQd2FPXPegDuI7iN+FJz05pAmxsKRz14rJs7lCFdSMZrbTawJAHNAEblipXFU5IM5ZThh1FaLdD7frVeQDPvQBUjEiyHkgdBmnZbJ4/CrBB2j0xSqoJAx15oAgRVlBSQ8+9U7vT2GfKXIHGMVqomZOg9yar3d+YgVgwADyfU0Acfe2cqXJOxtretTwAqyqo4TuelbgvzMCJ0BXHpVWeNADJCR5X6g0AZOoAmLOAcVhnk1t3EgZW54ORWIetAFiz/j/Ciiz/j/AAooAgl/1j/U02nS/wCsf6mm0AWLRsNj8a2bRs4HqKwFYqwI6itvT8SKCvQ847UAbEP6VoQ84+npWdakn7w5xWlBggDseKALUSjHTBPFR+Q7twpA96nixjg//Wq2nT2xQBVhtGB5UY+tW40Ebj8qlUdB1pJVPtQBYDcZPWlBIYBSQe9RwsCfTHFShfnzg/XNAFhHz93GO9P444x71EjAdTx2qvLc9QhwPWgC3JOqnAPPtVaS5fOQcVT85ixBP4UxXy3qooA2tJn8y6QMemcVDLLmaTkfeODUWnHy5ZJRwFU8/hVRHO760AaEjbsH0pUc+oAqqrblIPpipgxwCeM0AacUxVVAJ49eatrKCD0/xrHSTC46/jUglO0g8UAazzAD5Tz7VBLM655JFZ8Eh/XpV+SMvGCRz70AZ8l2x5bp061Ue5D5yWA71NPCc7SeO9VPJUFiWPHpQBIlz5a/KxFWIL1jtwwBz2qmsSEYy350+CNAR8pJPvQBspqWVG45Pf0qZLxGzlQAayH2KxXafXimoRnIJoA0jdoHIPT/ADxUiSpwQRz6isplOMj8zT9zbFCjjpwaANqKfIOBnbS31wRbiZUBJXGc1TsshgG/iGeRVx4zLaOgGCp3dexoA5O/vZHSQPwQp4xXF3995cvy5bIyPrXf3umGR3+UhWBBArgtX0qRJChUqVBHTFAHN3ckkspckkVHBnOSfpWsunStFtHP4UxNInUjaN/oBQBntEW+Y8c9KdBC8kmyMEnPpXRRaJJLEdyHIGR6Vo6ZpSWoBZfmPJwOKAKemWBjWNXYkbskV0cShB8vIHHNVCmz51GPQdKetzhcY5HFAFg9OgxjioHGWHWnwybwMke2DUZ70AGTgDOM/pQMgHHTtSk4wP0oGGPI460AF03lxhATlupqG0jTHmzDKr90HuaZM/mSH0+tLPKqIF3cKOfWgBLzyblWZEETCuXubwQOyZJHQitK6uy2QnHuTWFquyQlt4Lr1x3oAiv3CqCpzv5HtWfSsSTzSUAWbP8Aj/Ciiz/j/CigCCX/AFj/AFNNp0v+sf6mm0AFXtKuRDOEkOI24z6H1qjRQB29unYce9X4RjAIxisHw3fCZfs8p/fIPkP94f410qIGAzxj8qAHxcgelXIyQByKrxpxjFWYxzmgCynXk8fSnlc/Qe3SmRj65xUjKBySaAIfuMcZpz3KImSarzSEK+3t/Osq5kPQtgmgDrLHQta1SNZra32wt913YKPwrSg8B6rn968WfY1a+H/i5Psn2G9ZFkiOFbP3hXpkcilVO4YYZFAHmLeAb3P3k+uaQ+A7pCMzCvUiwxmolG6TJHSgDzhvBl7DayJE6sWGMk4rLk8H6nG2AqN9DXrcpAXp9KhVAecZoA8nHhrVI2INuW+hBzT5tA1REUm0fk9j2r08gGQ4GB1xTigYMc8CgDyl9HvYwG8lzjrUbRtESGVge+RXpssYOGI6muX8RSxRzmN0yWHBx0FAHN2oQMGbqTx7VslUMYIYDtWPAq+cYwc55AHrWmB8mPfHNAFK7t3YnABz6HvVJrWTPIGPrWxcQLIhBHPXI61mR2+99mxuOtACQ2eASxCls9anFmqNGfMHX0Jq6tmqBFUDIHP1qS5hCwr8vQ0AZs8EW/mTv02mq4ihVuZDjP8Adq/Kn7w8cE1RnVVJH8XU47UANcR9FlOM55XinQIj/wDLRfbjrVNnEQ6Fm9KqtcSl8IMZPT3oA7SxRA0RZwRn0z1rRSCOO4dT0I2nK4rD0N5WjRWbJBzzz+FdNeOCQ2OSASaAMC8iVRkHAPHSsS8iVpPmUMAMciumvYj5WQB8pzyaxbmJlQMBn19qAMc2UAJ/dLnPpxTUt4lAKRqD7CrZ4BPOaizzz0oAYox0A59KicBcgVMSOmKjk7Z69M0AULlVY4wM1mXJCgnPA/Wtlo+STgntVS6t1kQDbgA0AUYyGQYPapoZWKhW5I7+tCwonOfm9DSl0UhQMGgB5YY5WmSyFIzjkn1pT9/b2PpUVxycAe1ADIDuYOx6elRXALLkketTt8iKD1PXBqvI2VZTg5BoA528kZ5QqZyeB7VmXg2StHnLD7x960NRJtGDE4mP3fYetY/XrQAlFFFAFmz/AI/woos/4/wooAgl/wBY/wBTTadL/rH+pptABRRRQA+KR4pVkiYq6nII7GvQNB1CPU7bcMLMvEiZ6H1Hsa88q1p17Np92lxbth16g9GHcH2oA9TjTJBHWpVUnp0qnpF/DqVotxbnjgOueUb0Pt71qqvUj0/WgBFGD29qWRdyjnGKdt+XPYdhQw2jJ6ZoAyroBOACc88nis6bGFyDz2rUuVLSMcdDzVaeEAcp05GTQBlKWjkHkPtbkAqcGvX/AAb4iibw2kl5OA9moSUE8j0P415N9lZnBXGQa0LeGQB41DKWHzYPUe9AHvltqMV3aLcQSK0TgFTVqB9yBhg/SvKbTUptN8Oabb2vzzuzO4xwozgLXpennFjbh/vMgLexxQBPO/zdeKXcFX3PSs64uQ8oRDyDip5H2oBngCgCSIAu2fT86HYrGcg4qukwEu3PJGadeybLVmyOBQA6fGFAx61xviyUwXUIZQ0bAnnk10lxOxsSUwZAuVBHeuIubuTVkMMg/eICy59R1FAFUIEu4pByjEYIrQORwFJGetVbNDuQMQQpz7VpRYZ88cAke5oAFXABLcnqKiiQ+a20AZ7inlSz4HfqKtwxbU6cjigCOONt4IU496kliaSEEqck96sgbAMn35NOZ8x7em3pigDEuYyudwwCcVlXf3cdePpXRzNuyGHJNZ1zbq/Qc4/OgDmvJZ5WLZHoe1SxWyB89MfrWkbBudverFppxYlnzkdjQA/R9yKpzjFa0kjYAHzEcCqa27xxFh3P0xUzwO8QaIZPcCgCGZ8Z5JLcdap7jJuBIAI5z0qWdGBIbjA71n3B2kjn1oAgkdeg5PrVcjJ5FSuMnpj6UgXnPPFAEbdhjr1pp+4QRyakI5NNbap60AVnUuCcVXlQ8YJ+lWlYEYU5FRSqT0OKAM6WNw3qDUYwBkjGP1q7KBnkc1UIO2gBSQo3dcdDUCjcwJPSibAYAdhzilRsRjkbjQBBO2SSORVe4misrZrq5GQPuJnlz6VdcQwQPdXblIE6nufYepNcPq+oy6ldeZIAsa8Rxjoi+n/16AK93cSXdw80xy7HPHQewqGiigAooooAs2f8f4UUWf8AH+FFAEEv+sf6mm06X/WP9TTaACiiigAooooAvaRqU+l3az259nQ9HHoa9T0TUbfVLNZrVvl6Oh6ofQ/4968eq/o2qXOkXguLVhno6N91x6GgD2QryAetDqGAGAao6Bq9trVoJbdgsiD95CT8yH+o961dgGCBzmgCm9rv7cfSlFlHj58t6ZrRCAg9+9Eabm6dO1AFeGzhTBCKPU4q0LdDg7QMe1SonQn05qZV/D60AMjiTzIy4xGpBI/Hmu9S6jkUiNhwmQPauGxzk037XLaTNJExzsK4J4waANXQ9QE2rSJOeSSUPY10N7IAgweT2rzu1mMMiydXXkVfl1uZl5XJwOc4oA2/t62mqP5vKlML9avahfxy6UZgww+MfWuJvLs3E/mKMZHf1p0FxI9uLdgPLLbvoaAOtjvIn08SswQKDnmuLkl/0mSSH5Q5wOOgrQeNQQmSR1xngVU2AyBevfPpQBYtsJGuT96riADkdT2qmYixBUfLV2MYAGccUAXLR13fOuR0J9KsDjdt6HjmqMcmAM8etPBctlSc+nrQBZ4J5xkdKjfLg7COnpUyguoOGyPak8t9uQre9AGcxY5yeKaTluc9OtW3hYknYc54qNoWx8oOOlAFbGASc1JA7Kw5zjtTWRh6g+4p8Qw3bnr2oAvTIjRq4xuHBFV2cxKzRNz16VKpBQAAYB7VXcfKwPf9KAM+4lZs/wB445NZNzKFdlYrv6/StSU/fB+8O4rBkH75yRnJzQA/zARknqevrS7wRxUKx8kHpUirjAbPPFADSzbuoUVG7YHP5DvUhUdcYGaYynaSPy9aAIjwCQOD2pjHjNOJJ4I6Hr2qNuOc4+lAEEpyM4GRVZmCqx4xU0hzwPXGKpXj4TaMcnNADOZJO+e9SSNFbwvc3T+XBH1buT6AdyahMkFlaPdXj7I+ir/E59FHc1x2s6tPqkqmQBIU4jiU8L7+596AHa5q0uqXAJHl26f6uIHhR6n1J7msyiigAooooAKKKKALNn/H+FFFn/H+FFAEEv8ArH+pptOl/wBY/wBTTaACiiigAooooAKKKKALOn3txp90lzZytFMvRl9PQ+o9q9W8L+J7XXEWGTbb6h3iJ+V/dD/Tr9a8gpVYqwZSQwOQR2oA+ggOMdPrUkakZx1PWvO/Cvjrb5drrzMw6LdgZI/3x3+vX1zXpNvskjjkjdZInG5HQgqw9Qe9AD0H0B+lPA/I0oBz0p5TK+tAFaVcw4XrVFixc7gfQ1rEEqBg4x+VRtCpTplhQBi7MScZIzUwQ5xxyO9W2i54GTSFQCeOaAKZg3SAtwv86lSLGOTgdRU4jz93rmnFDn8OKALMe3CllyQMUfL5mQo6Gox0UClJyPagB5kDYAIqSMjPTP41UYZ9u1IBheOlAGh5u3oq+hzTvtRI424PSs0LvcDketWFUGRQPWgC3BdvggMBg4OetSfamONzAisuIbXmyOAc01mJzwcjtQBqCcgnJX60wzlTwVPNZ8Mm3Abp3qdunAAoAnN2VBygPrzTxNbsvzqykjsc1QA4LBcA07bxzQBqWrQO+0SjJ4wwx9KgvQEdhuXPPeq8JIXI4IOc1a1RcybuMMgPH0oAxp33MSAcHtis2aMh2POPStR1w+Rx2IpkiZUcZ9KAMoDP+FNbI4xkVZlj5JGc57iq7dcZzQAg5APemsOnanHp1H51G7DHNAEMp4OOcHmoJOEINSuep71XkIBOOmM+2KAIWYD5m7frWLquoQWKsZyHmblYR1PuT2FVNd8RRx5g08rJIODN1UH/AGfX61yUjvJIzyMWdjksTkmgCzqV/cahP5ty+cDCqPuoPQCqlFFABRRRQAUUUUAFFFFAFmz/AI/woos/4/wooAgl/wBY/wBTTadL/rH+pptABRRRQAUUUUAFFFFABRRRQAVveGPFOpeHpCLSQSWrHMltKNyN/gfcYNYNFAHv3hnxVpHiNUSCT7LfEYNrMwBJ/wBhujfTr7VvSRNGcYPBr5kBKkFSQRyCO1d14Z+JGp6aqW+pg6jaDgGRsSoPZ+/0OfwoA9eyOD0p6qpbnk1neHtf0jxEgGnXSmfGTbS/JKPoP4vwzWyYCoPX0IoAqSxAEnHGagMYzV5VyCDkevajyBjGRQBSCDGP5UmAP/rVcaA54phhO3OMd80AUmHOOeKcBk1N5fzdqnijUDI5J9aAKLof4c5qIggYAP1rZUAk5QH0qRbWDGZVIOOzUAY9pEzSMxU4C8Z9asxqRImR371or9mVG27gT69MVGEjdh82OaAM9oyk7jvmqjqd5B+mPWte4iiW4cGQAkZ6VRnjj3ECXNAFEr8xAGAKtxlmTkEkUxY0JGZefWpoYw7lfOBHYUAI0ijj+QpAQxyuD/OpTaxnrMvr0ojihU583JHoKAEhkAcbuUPBq/dDzFXcMADA+lV4xCZF2qxBPfitKYr5SqqjIzQBz0y/OR6GmFMrzjvmrl1bMWLqMAnkCotgK4Yc479aAMqXqSKpynDMcYFXrmIoCGOfSqM6MW4459aAIZW4z2qFmBJ7g1Bql/a6bHuv5liOMhOrt9B/kVxOq+LLicNHp6m3jPG8nLkf0/D86AOo1bVrPTFJuJN0vaFfvn6+n41w2sa5dakShPlW/aNT1+p71luzOxZ2LMeSSck02gAooooAKKKKACiiigAooooAKKKKALNn/H+FFFn/AB/hRQBBL/rH+pptSyIxkfCt1PameW/9xvyoAbRTvLf+435UeW/9xvyoAbRTvLf+435UeW/9xvyoAbRTvLf+435UeW/9xvyoAbRTvLf+435UeW/9xvyoAbRTvLf+435UeW/9xvyoAbRTvLf+435UeW/9xvyoAEZkYMjFWByCDgiu28PfErWtKRIbopqVsvAW4zvA9A45/PNcT5b/ANxvyo8t/wC435UAe+6H4+8OavhJbhtPuG/guuFz7OOPzxXSpGdgeNhJC/KyIQyn6EcGvl3y3/uN+Vamj61rGjPu0u9urbPVUY7T9V6GgD6O5Ud80rAEenevJNM+KepxYXVNPguh0LxgxP8Aplf0rr9M+IOgXwCzSXFjITjbcREr/wB9Ln9QKAOnKck460IoRh6Z6d6SyvLS9TdY3UFyo5/dSBj+I6irDxsein8qAJvL8tC/QnpVWbO7A5X1rQETvZRHDEglWqq0LZ+6cdDxQBnuevGCP0p8TETDrnParBtXdshSak+yleFB+uKAK07iSct29KzJQQ3HBzitW6hdRhVPrnFVXic87Wx9O9AFHaemDgnFSRqVYDkE1aSFiRgE8kdKsfZyMHaSw4PFAFVlII4z9aI4mz0wM9atyIRzgjPtmkCsWXjp2oAkW3aNY3BDKeo96S4nOTx05+lWmubW2s2N7cQWycYaaQJz7ZPP4VxWv+NtBtXYJdSXrrxttYyQf+BHAoA6KacD5c5A569aqSXIEhO3CryWJ4FeZ6l8RLpwy6bp6Qg/xzEufy4H865HU9Y1XUyft11PKv8Ac6L/AN8jigD03XfFel2U0m65FxL/AM84Pn/8e6VxGreNb+7DJZqtnF6r8z/99Hp+GK5fy3/uN+VHlv8A3G/KgBZJHlcvIzO56sxyTTKd5b/3G/Kjy3/uN+VADaKd5b/3G/Kjy3/uN+VADaKd5b/3G/Kjy3/uN+VADaKd5b/3G/Kjy3/uN+VADaKd5b/3G/Kjy3/uN+VADaKd5b/3G/Kjy3/uN+VADaKd5b/3G/Kjy3/uN+VAE9n/AB/hRTrNG+f5W7dqKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Corkscrew or angulated sleeve gastrectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7473=[""].join("\n");
var outline_f7_19_7473=null;
var title_f7_19_7474="Severe fetal scoliosis";
var content_f7_19_7474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound showing severe fetal scoliosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A: abdomen; LSP: lower spine showing curvature.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of SM Jenkins, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7474=[""].join("\n");
var outline_f7_19_7474=null;
var title_f7_19_7475="Penciclovir: Pediatric drug information";
var content_f7_19_7475=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penciclovir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"    see \"Penciclovir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/20/33091?source=see_link\">",
"    see \"Penciclovir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Denavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"      see \"Penciclovir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Children &ge;12 years, Adolescents, and Adults: Apply every 2 hours during waking hours for 4 days; start at the first sign or symptom of cold sore (eg, tingling, redness, itching, swelling)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denavir&reg;: 1% (1.5 g, 5 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply only to herpes labialis on the lips and face. Apply sufficient amount to cover lesions and gently rub into the affected area. Avoid application in or near eyes since it may cause irritation.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of recurrent herpes labialis (cold sores, fever blisters) (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Denavir&reg; may be confused with indinavir",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F207432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Mild erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Erythematous rash, local anesthesia, local edema, oropharyngeal edema, pain, paresthesia, parosmia, pruritus, skin discoloration, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penciclovir, famciclovir, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available on safety and efficacy of penciclovir application to mucous membranes; avoid application to mucous membranes or near the eyes. Efficacy has not been established in immunocompromised patients or children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13376203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies following intravenous administration.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resolution of pain and healing of cold sore lesion",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In cells infected with HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form which is converted to penciclovir triphosphate by cellular kinases. Penciclovir triphosphate inhibits HSV polymerase by competing with deoxyguanosine triphosphate inhibiting viral DNA synthesis and replication.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1049202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Resolution of pain: Adults: 3.5 days (Spruance, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cutaneous healing: Adults: 4.8 days (Spruance, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Topical: Negligible",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/20/33091?source=see_link\">",
"      see \"Penciclovir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This is not a cure for herpes (recurrences tend to appear within 3 months of original infection), nor will this medication reduce the risk of transmission to others when lesions are present. For external use only on lips and face. Do not use in or near eyes. Wash hands before and after application. Apply cream over affected areas at first sign of cold sore (eg, tingling, redness, itchiness, or swelling). Headache, mild rash, or taste disturbances may occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penciclovir is the active metabolite of the prodrug famciclovir.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dekker CL and Prober CG, &ldquo;Pediatric Uses of Valacyclovir, Penciclovir and Famciclovir,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2001, 20(11):1079-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/19/7475/abstract-text/11734715/pubmed\" id=\"11734715\" target=\"_blank\">",
"        11734715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spruance SL, Rea TL, Thoming C, et al, \"Penciclovir Cream for the Treatment of Herpes Simplex Labialis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Topical Penciclovir Collaborative Study Group,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(17):1374-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/19/7475/abstract-text/9134943/pubmed\" id=\"9134943\" target=\"_blank\">",
"        9134943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12911 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-31B8A52DC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7475=[""].join("\n");
var outline_f7_19_7475=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049197\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049191\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207390\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207375\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049200\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049193\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049199\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207433\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207432\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049204\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049190\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299836\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207384\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207386\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376203\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049196\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049202\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049203\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049195\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049205\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12911\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12911|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=related_link\">",
"      Penciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/20/33091?source=related_link\">",
"      Penciclovir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_19_7476="Iothalamate meglumine: Patient drug information";
var content_f7_19_7476=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Iothalamate meglumine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4499?source=see_link\">",
"     see \"Iothalamate meglumine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Conray&reg;;",
"     </li>",
"     <li>",
"      Conray&reg; 30;",
"     </li>",
"     <li>",
"      Conray&reg; 43;",
"     </li>",
"     <li>",
"      Cysto-Conray&trade; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15793707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Conray&reg; 30;",
"     </li>",
"     <li>",
"      Conray&reg; 43;",
"     </li>",
"     <li>",
"      Conray&reg; 60;",
"     </li>",
"     <li>",
"      Cysto-Conray&trade; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein only.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705260",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to iothalamate meglumine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12067 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7476=[""].join("\n");
var outline_f7_19_7476=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15793707\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025476\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025478\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025477\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025481\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025482\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025484\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025480\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025485\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025486\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4499?source=related_link\">",
"      Iothalamate meglumine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_19_7477="Leukoplakia PI";
var content_f7_19_7477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F62948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F62948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Leukoplakia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Leukoplakia causes white or gray patches in the mouth or on the tongue. Photo A shows leukoplakia on the inside on the cheek. Photo B shows leukoplakia on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7477=[""].join("\n");
var outline_f7_19_7477=null;
var title_f7_19_7478="Propafenone: Patient drug information";
var content_f7_19_7478=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Propafenone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     see \"Propafenone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rythmol&reg;;",
"     </li>",
"     <li>",
"      Rythmol&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Propafenone&reg;;",
"     </li>",
"     <li>",
"      Mylan-Propafenone;",
"     </li>",
"     <li>",
"      PMS-Propafenone;",
"     </li>",
"     <li>",
"      Rythmol&reg; Gen-Propafenone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to treat unsafe fast heartbeats only. It may cause risky side effects. You will be closely watched when starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691685",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartbeats that are not normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702805",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to propafenone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4199492",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Breathing problems, Brugada syndrome, electrolyte problems in your blood, low blood pressure, recent heart attack, slow heartbeat without a working pacemaker, or weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4199623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: QTc-prolonging drugs like amiodarone, arsenic trioxide, chlorpromazine, cisapride, dofetilide, dolasetron, droperidol, mefloquine, moxifloxacin, pentamidine, pimozide, procainamide, quinidine, sotalol, tacrolimus, and thioridazine. Ask your doctor if you are  not sure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4199493",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you take any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain drugs that are used for HIV, infections, or depression. There are many drugs that must not be taken with this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4199626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a pacemaker, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may affect certain lab tests. Be sure your doctor and lab workers know you take this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4199625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may lower sperm counts in men. This may affect being able to father a child. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need an ECG before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an ECG checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in taste.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4192396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling sleepy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4186197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark, tarry-black stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4192394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A burning, numbness, or tingling feeling that is not normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unable to pass urine or change in the amount of urine passed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain when passing urine or blood in urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablets with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11227 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7478=[""].join("\n");
var outline_f7_19_7478=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214329\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214330\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022684\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022686\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022685\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022690\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022691\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022693\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022688\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022689\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022694\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022695\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=related_link\">",
"      Propafenone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_19_7479="Busulfan: Pediatric drug information";
var content_f7_19_7479=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Busulfan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"    see \"Busulfan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/32/36357?source=see_link\">",
"    see \"Busulfan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Busulfex&reg;;",
"     </li>",
"     <li>",
"      Myleran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Busulfex&reg;;",
"     </li>",
"     <li>",
"      Myleran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"      see \"Busulfan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols; dose should be based on ideal body weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Remission induction of CML: 0.06-0.12 mg/kg once daily",
"     <b>",
"      or",
"     </b>",
"     1.8-4.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily; titrate dose to maintain a leukocyte count &gt;40,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; discontinue busulfan if counts fall to &le;20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BMT marrow-ablative conditioning regimen: 1 mg/kg/dose every 6 hours for 16 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hematopoietic stem cell transplant regimen: Children &le;6 years: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 6 hours for 16 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: High-dose BMT or peripheral blood progenitor cell transplantation conditioning regimen: Dose based on actual body weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;12 kg: 1.1 mg/kg/dose every 6 hours for 16 doses over 4 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;12 kg: 0.8 mg/kg/dose every 6 hours for 16 doses over 4 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment based on therapeutic drug monitoring:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose (mg) = Actual dose (mg) x target AUC (micromolar&bull;minute) / actual AUC (micromolar&bull;minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Target AUC = 1125 micromolar&bull;minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Remission induction of CML: 4-8 mg/day or 0.06 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: Controversial; range is from 1-4 mg/day to 2 mg/week; reduce dose in proportion to the decrease in leukocyte count or discontinue busulfan when the leukocyte count falls to &le;20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: High-dose BMT conditioning regimen: 0.8 mg/kg/dose every 6 hours for 16 doses over 4 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. dose for obese patients: Dose should be based on adjusted ideal body weight (AIBW)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AIBW = Ideal body weight (IBW) + 0.25 x (actual weight - IBW)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Busulfex&reg;: 6 mg/mL (10 mL) [contains N,N-dimethylacetamide (DMA), polyethylene glycol 400]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myleran&reg;: 2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to meals. To facilitate ingestion of high doses, insert multiple tablets into clear gelatin capsules for administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Filter busulfan using 5 micron syringe filter provided, using one filter per ampul. If using the syringe filter in the forward flow direction, allow for &sim;0.16 mL of residual busulfan to remain in the filter. Dilute busulfan injection with either NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W to a final concentration of &ge;0.5 mg/mL (diluent volume should be 10 times the volume of busulfan injection); infuse over 2 hours through a central venous catheter; flush line before and after each infusion with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS. Do",
"     <b>",
"      not",
"     </b>",
"     use polycarbonate syringes or filters.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F143441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at room temperature. Store intact ampuls in the refrigerator; diluted busulfan solution is stable for up to 8 hours at room temperature; infusion must be completed within that 8 hour time frame. If diluted in NS, the solution is stable for 12 hours if refrigerated, but the infusion must be completed within that 12-hour time frame.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic myelogenous leukemia (CML); component of marrow-ablative conditioning regimen prior to bone marrow transplantation (BMT) for refractory leukemias, lymphomas, and pediatric solid tumors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Myleran&reg; may be confused with Alkeran&reg;, Leukeran&reg;, melphalan, Mylicon&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F143440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, atrial fibrillation, cardiomegaly, chest pain, ECG abnormal, edema, heart block, heart failure, hyper-/hypotension, hypervolemia, pericardial effusion, tachycardia, tamponade, thrombosis, vasodilation, ventricular extrasystoles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, cerebral hemorrhage, chills, confusion, delirium,  depression, dizziness,  encephalopathy, fever, hallucination, headache, insomnia, lethargy, pain, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, erythema nodosum, exfoliative dermatitis, maculopapular rash, pruritus, rash, skin discoloration, vesicular rash, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal fullness, abdominal pain, anorexia, constipation, diarrhea, dyspepsia, esophagitis, hematemesis, ileus, mucositis/stomatitis, nausea, pancreatitis, rectal disorder, vomiting, weight gain, xerostomia,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, lymphopenia, myelosuppression, neutropenia (median recovery: 13 days), prothrombin time increased, thrombocytopenia (median onset: 5-6 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease), hepatomegaly, hyperbilirubinemia, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site inflammation/pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: BUN/creatinine increased, dysuria, hematuria, hemorrhagic cystitis, oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Alveolar hemorrhage, asthma, atelectasis, cough, dyspnea, epistaxis, hemoptysis, hiccup, hyperventilation, hypoxia, lung disorder, pharyngitis, pleural effusion, pneumonia, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, infection (includes severe bacterial, viral [CMV], and fungal infections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperpigmentation of skin, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, ovarian suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (anemia, leukopenia, thrombocytopenia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. and/or Oral:",
"     </b>",
"     Rare but important or life-threatening: Acute leukemias, adrenal insufficiency, alopecia (permanent), aplastic anemia (may be irreversible), azoospermia, bronchopulmonary dysplasia, capillary leak syndrome, cataracts (rare), cheilosis, cholestatic jaundice, corneal thinning, dry skin, endocardial fibrosis, erythema multiforme, esophageal varices, gynecomastia, hepatic dysfunction, hepatocellular atrophy, hyperuricemia, hyperuricosuria, interstitial pulmonary fibrosis, malignant tumors, myasthenia gravis, neutropenic fever, ocular (lens) changes, ovarian failure, pancytopenia, porphyria cutanea tarda, pulmonary fibrosis, radiation myelopathy, radiation recall (skin rash), sepsis, sterility, testicular atrophy, thrombotic microangiopathy (TMA), tumor lysis syndrome, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to busulfan or any component; failure to respond to previous courses; should not be used in pregnancy or lactation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . For the I.V. formulation, the physician should be experienced in management of hematopoietic stem cell transplantation and management of patients with severe pancytopenia. According to the manufacturer, oral busulfan should not be used until CML diagnosis has been established. Seizures have been reported with busulfan; use with caution in patients predisposed to seizures, with a history of seizures or head trauma. When using as a conditioning regimen for transplant, initiate prophylactic anticonvulsant therapy (eg, phenytoin) prior to treatment. Phenytoin increases busulfan clearance by &ge;15%; busulfan kinetics and dosing recommendations for high-dose HSCT conditioning were studied with concomitant phenytoin. If alternate anticonvulsants are used, busulfan clearance may be decreased and dosing should be monitored accordingly.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Bronchopulmonary dysplasia with pulmonary fibrosis (&ldquo;busulfan lung&rdquo;) is associated with busulfan; onset is delayed with symptoms occurring at an average of 4 years (range: 4 months to 10 years) after treatment; may be fatal. Symptoms generally include a slow onset of cough, dyspnea and fever (low-grade), although acute symptomatic onset may also occur. Diminished diffusion capacity and decreased pulmonary compliance have been noted with pulmonary function testing. Differential diagnosis should rule out opportunistic pulmonary infection or leukemic pulmonary infiltrates; may require lung biopsy. Discontinue busulfan if toxicity develops. Pulmonary toxicity may be additive if administered with other cytotoxic agents also associated with pulmonary toxicity. Busulfan is potentially carcinogenic; malignant tumors and acute leukemias have been reported; chromosomal alterations may also occur. Busulfan use has also been associated with ovarian failure including failure to achieve puberty and amenorrhea in females",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause significant bone marrow suppression even with recommended dosages",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may result in severe neutropenia, thrombocytopenia, anemia, bone marrow failure, and/or severe pancytopenia; pancytopenia may be prolonged (1 month up to 2 years) and may be reversible. Use with caution in patients with compromised bone marrow reserve (due to prior treatment or radiation therapy); reduce dosage in patients with bone marrow suppression; monitor closely for signs of infection (due to neutropenia) or bleeding (due to thrombocytopenia). High busulfan AUC values (&gt;1500 micromolar/minute) may be associated with an increased risk of developing hepatic sinusoidal obstruction syndrome [SOS; formerly called veno-occlusive disease (VOD)]; reported incidence 7.7% to 12% with high-dose busulfan; patients who have received prior radiation therapy, &ge;3 cycles of chemotherapy, or prior progenitor cell transplant are also at increased risk for developing HVOD. Oral busulfan doses above 16 mg/kg (based on IBW) and concurrent use with alkylating agents may also increase the risk for hepatic SOS. Of the patients who developed HVOD, it was fatal in 40% of the cases; monitor liver function tests periodically. Cardiac tamponade has been reported in a small number of patients with thalassemia treated with high-dose oral busulfan in combination with cyclophosphamide.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The solvent in busulfan injection is dimethylacetamide (DMA); DMA may impair fertility and may also be associated with hepatotoxicity, hallucinations, somnolence, lethargy, and confusion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: Busulfan may enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk of hemorrhagic cystitis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Busulfan. Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1045653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No clear or firm data on the effect of food on busulfan bioavailability",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3880598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm if administered during pregnancy. The solvent in I.V. busulfan, DMA, is also associated with teratogenic effects and may impair fertility. Women of childbearing potential should avoid pregnancy while receiving busulfan treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, hemoglobin, liver function tests, bilirubin, alkaline phosphatase; monitor busulfan plasma concentration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with the normal function of DNA by alkylation of intracellular nucleophiles and cross-linking the strands of DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 70% absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses into CSF, saliva, placenta, and liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 0.64 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 32% to 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver by conjugation with glutathione",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.3-2.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 10% to 50% excreted in urine as metabolites, 1% excreted unchanged in urine within 24 hours; total plasma clearance rate is 2-4 times higher in children than in adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 3.37 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 2.52 mL/minute/kg (range: 1.49-4.31 mL/minute/kg)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/32/36357?source=see_link\">",
"      see \"Busulfan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any difficulty in breathing, cough, fever, sore throat, bleeding or bruising to physician. Report any signs of abrupt weakness, fatigue, anorexia, weight loss, nausea, vomiting, and melanoderma. Female patients of childbearing potential should avoid becoming pregnant during and for one month following therapy.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One method used to prevent seizures during high-dose busulfan (&sim;4 mg/kg/day for 4 days) is to initiate a standard loading dose of phenytoin (15 mg/kg) 1 day prior to starting busulfan therapy followed by a maintenance dose adjusted to maintain a therapeutic phenytoin concentration until 24 hours after the final busulfan dose",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     &ldquo;Juvenile type&rdquo; chronic myelogenous leukemia which typically occurs in young children and is associated with the absence of Philadelphia chromosome responds poorly to busulfan.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10893684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 2 mg/mL oral suspension can be prepared in a vertical flow hood with tablets and simple syrup. Crush one-hundred-twenty 2 mg tablets in a mortar and reduce to a fine powder. Add small portions of simple syrup and mix to a uniform paste; mix while adding the simple syrup in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a graduated cylinder, rinse mortar and pestle with simple syrup, and add quantity of vehicle sufficient to make 120 mL. Transfer contents of the graduated cylinder into an amber prescription bottle. Label &ldquo;shake well&rdquo;, &ldquo;refrigerate&rdquo;, and &ldquo;caution chemotherapy&rdquo;. Stable for 30 days.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV, \"Busulfan Oral Suspension,\"",
"     <i>",
"      US Pharm",
"     </i>",
"     , 1990, 15:94-5.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bolinger AM, Zangwill AB, Slattery JT, et al, &ldquo;An Evaluation of Engraftment, Toxicity and Busulfan Concentration in Children Receiving Bone Marrow Transplantation for Leukemia or Genetic Disease,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2000, 25(9):925-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/19/7479/abstract-text/10800058/pubmed\" id=\"10800058\" target=\"_blank\">",
"        10800058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heard BE and Cooke RA, &ldquo;Busulphan Lung,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 1968, 23(2):187-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/19/7479/abstract-text/5240498/pubmed\" id=\"5240498\" target=\"_blank\">",
"        5240498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ozkaynak MF, Weinberg K, Kohn D, et al, &ldquo;Hepatic Veno-Occlusive Disease Post-Bone Marrow Transplantation in Children Conditioned With Busulfan and Cyclophosphamide: Incidence, Risk Factors, and Clinical Outcome,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1991, 7(6):467-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/19/7479/abstract-text/ 1908340 /pubmed\" id=\" 1908340 \" target=\"_blank\">",
"        1908340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Regazzi MB, Locatelli F, Buggia I, et al, &ldquo;Disposition of High Dose Busulfan in Pediatric Patients Undergoing Bone Marrow Transplantation,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(1):45-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/19/7479/abstract-text/8330465/pubmed\" id=\"8330465\" target=\"_blank\">",
"        8330465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vassal G, Gouyette A, Hartmann O, et al, &ldquo;Pharmacokinetics of High-Dose Busulfan in Children,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1989, 24(6):386-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/19/7479/abstract-text/2791192/pubmed\" id=\"2791192\" target=\"_blank\">",
"        2791192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13103 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7479=[""].join("\n");
var outline_f7_19_7479=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708634\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143389\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143390\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045642\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045635\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143366\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143351\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045646\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143441\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045638\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045645\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143443\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143440\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045650\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045634\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045633\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143428\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143360\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045653\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143362\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3880598\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045641\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045632\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045649\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045640\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045651\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10893684\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13103\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13103|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=related_link\">",
"      Busulfan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/32/36357?source=related_link\">",
"      Busulfan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_19_7480="Dyskeratosis congenita";
var content_f7_19_7480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Clinical features of dyskeratosis congenita",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photographs showing the classical mucocutaneous features of dyskeratosis congenita: (A) tongue leucoplakia, (B) nail dystrophy, (C and D) reticular skin pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7480=[""].join("\n");
var outline_f7_19_7480=null;
var title_f7_19_7481="Heart failure PA II";
var content_f7_19_7481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72562%7EPULM%2F58394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72562%7EPULM%2F58394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This chest radiography shows severe heart failure with cardiomegaly, pulmonary vascular congestion with infiltrates in the mid lung fields (white arrow), and a small pleural effusion (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cardiogenic pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary edema in a \"butterfly distribution\" due to left ventricular failure. Chest radiograph shows large perihilar opacities in patient with enlarged cardiac silhouette.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7481=[""].join("\n");
var outline_f7_19_7481=null;
var title_f7_19_7482="Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)";
var content_f7_19_7482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/19/7482/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/19/7482/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/19/7482/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/19/7482/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/19/7482/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/19/7482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/19/7482/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/19/7482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) that often has a poor prognosis. In a retrospective study of 619 patients with SSc, 40 percent of patients had a restrictive ventilatory defect (suggesting interstitial lung disease, ILD) either alone or in combination with pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/1\">",
"     1",
"    </a>",
"    ]. Herein, we discuss the prognosis and treatment of SSc-associated ILD.",
"   </p>",
"   <p>",
"    The clinical presentation and diagnosis of SSc lung disease and the treatment of SSc and SSc-associated pulmonary arterial hypertension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35382?source=see_link\">",
"     \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term ILD is broadly used to describe a heterogeneous group of disorders that are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations.",
"   </p>",
"   <p>",
"    In the vast majority of patients with SSc-associated ILD, the lung injury is characterized by a pattern termed nonspecific interstitial pneumonia (NSIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/2\">",
"     2",
"    </a>",
"    ]. Histopathologically, NSIP is characterized by varying degrees of pulmonary inflammation and fibrosis, with some forms being primarily inflammatory (cellular NSIP) and others primarily fibrotic (fibrotic NSIP). Most investigators believe that cellular NSIP is the early stage of fibrotic NSIP. Although NSIP may have significant fibrosis, it is usually of uniform temporality. Fibroblastic foci and honeycombing, if present, are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H18#H18\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Nonspecific interstitial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a minority of patients with SSc-associated ILD, the histopathologic pattern is that of usual interstitial pneumonia (UIP). This pattern is characterized by a non-uniform distribution of alternating zones of dense fibrosis, fibroblast foci, scant inflammation, normal lung, and honeycomb change.",
"   </p>",
"   <p>",
"    In this topic review, we refer broadly to SSc-associated ILD and do not distinguish among the histopathologic subtypes. Historically, SSc-associated ILD has been referred to by various terms, such as fibrosing alveolitis, interstitial pulmonary fibrosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    idiopathic interstitial pneumonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with systemic sclerosis (SSc), interstitial lung disease (ILD) predicts increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. This was illustrated by a retrospective study of 953 patients with SSc; patients with severe ILD had a nine-year survival rate of approximately 30 percent, whereas patients with SSc who did not have severe involvement of an organ system had a nine-year survival rate of 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/4\">",
"     4",
"    </a>",
"    ]. The most rapid decline in forced vital capacity (FVC) occurred within the initial three years of disease onset, indicating that lung injury and fibrosis are early complications.",
"   </p>",
"   <p>",
"    The prognostic value of lung biopsy in patients with SSc-associated ILD is limited; symptomatic and physiologic severity of the ILD are better predictors of outcome than histopathologic subtype. In a retrospective histopathological evaluation of 80 patients with SSc and biopsy proven ILD, 76 percent had nonspecific interstitial pneumonia (NSIP) and 11 percent had usual interstitial pneumonia (UIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/5\">",
"     5",
"    </a>",
"    ]. The five-year survival rate for patients with NSIP and UIP was similar, 82 and 91 percent, respectively. Markers of a worse prognosis included a lower diffusion capacity (DLCO) and a more rapid decline of DLCO over three years.",
"   </p>",
"   <p>",
"    The prognostic value of BAL is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/5,10-12\">",
"     5,10-12",
"    </a>",
"    ]. Although one retrospective study reported that increased eosinophils in the BAL fluid was associated with a poorer prognosis, a larger prospective cohort study of 141 patients with SSc-associated ILD found that the proportion of eosinophils in the BAL fluid did not correlate with increased mortality, rate of functional deterioration, or progression-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. An increased proportion of neutrophils in BAL fluid was associated with more extensive lung disease on high resolution computed tomography (HRCT), a greater reduction in diffusing capacity (DLCO), and early mortality (HR 8.40, 95% CI 1.91-36.95), but it did not predict the rate of functional deterioration or progression-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/10\">",
"     10",
"    </a>",
"    ]. In a prospective clinical trial of 158 patients with early-stage SSc and symptomatic lung involvement, the presence or absence of BAL fluid neutrophilia did not predict rate of worsening or response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic sclerosis (SSc)-associated interstitial lung disease (ILD) probably results from parenchymal lung injury, followed by inflammation and subsequent fibrosis. Inflammation is the target of therapy since fibrosis of the lung parenchyma is irreversible. Thus, the ideal candidate for treatment is the patient who has active alveolar and interstitial inflammation.",
"   </p>",
"   <p>",
"    The potential benefit of treatment must be weighed against the risks of therapy on a case-by-case basis. Unfortunately, the decision about whether to initiate therapy can be difficult because the benefits of therapy appear to be modest and the toxicities can be significant.",
"   </p>",
"   <p>",
"    We suggest that immunosuppressive therapy be initiated in patients with SSc-associated ILD who have respiratory symptoms, abnormal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    declining pulmonary function, evidence of active (ie, progressive) disease, and no contraindications, because these patients have high risk of progressive lung disease and increased mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Active disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of active (ie, progressive) disease include an early disease stage, abnormal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    declining pulmonary function, and possibly ground glass opacity on high resolution computed tomography (HRCT).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease stage &ndash; Patients with early SSc-associated ILD are more likely to have active inflammation and to respond to pharmacologic intervention than those with long-standing disease. Although there is no uniform agreement on how early disease should be defined, it generally refers to the initial 12 to 24 months of disease, before significant irreversible organ fibrosis is established. This concept is supported by a retrospective study that compared the response to different therapies in 122 patients with SSc-associated ILD [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/14\">",
"       14",
"      </a>",
"      ]. Regardless of the therapy, patients with early disease were more likely to have improvement of pulmonary function than those with longer disease duration.",
"     </li>",
"     <li>",
"      Pulmonary function &ndash; Pulmonary function tests demonstrating a restrictive ventilatory defect and decreased diffusing capacity for carbon monoxide (DLCO) are consistent with SSc-associated ILD. Serial tests that demonstrate worsening pulmonary function are an indicator of active disease.",
"     </li>",
"     <li>",
"      High-resolution computed tomography (HRCT) &ndash; Early studies suggested that ground-glass opacification on HRCT is due to inflammatory infiltration of the interstitium and alveoli (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70357 \" href=\"UTD.htm?34/35/35381\">",
"       image 1",
"      </a>",
"      ), while reticular or nodular abnormalities on HRCT are more likely due to parenchymal fibrosis. Subsequent studies however failed to demonstrate a correlation between ground-glass opacification and alveolar inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"       \"High resolution computed tomography of the lungs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchoalveolar lavage (BAL) &ndash; In some centers, BAL is performed as a part of the evaluation to exclude pulmonary infection, which may be important in patients already receiving immunosuppressive therapy for SSc. However, findings on BAL analysis do not appear to predict progression of lung disease or response to therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]. There is, therefore, insufficient evidence to recommend performing BAL for assessment of disease activity or likelihood of treatment response. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active or suspected infection is the most common contraindication to immunosuppressive therapy. Pregnant, lactating, or neutropenic patients should also avoid immunosuppressive therapy. Patients with a history of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -related hemorrhagic cystitis should not be prescribed cyclophosphamide again.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small number of randomized, controlled therapeutic trials have been performed in patients with systemic sclerosis (SSc)-related interstitial lung disease (ILD). It is difficult to recruit patients for placebo-controlled studies because of the high risk of disease progression. In addition, clinical heterogeneity (eg, diffuse versus limited SSc, early- versus late-stage disease), varying disease severity, and varying rates of progression complicates analysis of results. Therefore, there is a paucity of outcome data to guide treatment decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision has been made to initiate therapy, we advocate intravenous monthly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    together with low dose oral glucocorticoids (equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &le;10",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Liberal fluid intake is encouraged during therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    plus glucocorticoid is an alternative regimen that can be considered for patients with contraindications to cyclophosphamide or who decline cyclophosphamide. Data supporting these regimens are presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in the treatment of scleroderma lung disease remains unclear due to the toxicity of cyclophosphamide and conflicting data regarding efficacy. Randomized trials using both oral and intravenous routes of administration suggest that cyclophosphamide imparts modest benefit in SSc patients with early, symptomatic disease, whether administered orally or intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. However, a meta-analysis of three randomized trials and six open label studies did not confirm an improvement in pulmonary function (ie, forced vital capacity and diffusing capacity for carbon monoxide) with cyclophosphamide after 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General guidelines for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients in studies evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    versus placebo in SSc-associated ILD have also been on a low dose glucocorticoid. It is for this reason that we usually use a low dose glucocorticoid in combination with cyclophosphamide. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adjuvant glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    appears to be beneficial for some patients with symptomatic SSc-associated ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/13,17-19\">",
"     13,17-19",
"    </a>",
"    ], although not all studies have confirmed this finding as noted above. Improvement in pulmonary function was demonstrated in a double-blind, multicenter trial (the Scleroderma Lung Study) that randomly assigned 158 patients with early SSc-associated ILD, dyspnea, and evidence of active alveolar inflammation to receive either oral cyclophosphamide (&le;2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo daily for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/13\">",
"     13",
"    </a>",
"    ]. Evidence of active alveolar inflammation included ground-glass opacities on high resolution computed tomography, or elevated neutrophils or eosinophils in bronchoalveolar lavage fluid. Concomitant glucocorticoids were permitted, but only in doses equivalent to &le;10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Outcomes at 12 months were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      group had a smaller decline than the placebo group in forced vital capacity (-1 versus -2.6 percent of predicted) and total lung capacity (-0.3 versus -2.8 percent of predicted). Diffusion capacity was the same in both groups.",
"     </li>",
"     <li>",
"      In a portion of the patients, scoring of high resolution computed tomography (HRCT) scans for fibrosis (defined as reticular intralobular interstitial thickening, traction bronchiectasis, bronchiectasis, or any combination), ground glass opacities, and honeycomb cysts was performed at study onset and repeated after one year [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/20\">",
"       20",
"      </a>",
"      ]. The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      group had relatively less progression of fibrosis compared to the placebo group. No differences between the groups were noted regarding changes in ground glass opacities or honeycomb cysts. Subsequent analysis found that more severe fibrosis on HRCT was an independent predictor of a response to cyclophosphamide (improvement in forced vital capacity at 18 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measures of skin thickness, dyspnea severity, and self-reported disability also favored",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      group had modest improvement in measures of health related quality of life, compared to those in the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse events occurred more frequently in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -treated group. Among the 79 patients who received cyclophosphamide, nine developed hematuria, 19 developed reversible leukopenia, seven developed neutropenia, and five developed pneumonia within the 12 month treatment period. One patient developed severe hemorrhagic cystitis requiring surgery and three patients developed cancer. The duration of this trial was insufficient to assess the true incidence of cyclophosphamide-associated cancers (bladder, hematological, and skin cancers), because they may not become apparent for many years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results indicate that a one-year course of oral daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has modest clinical efficacy for the treatment of patients with early SSc and active symptomatic alveolitis. However, the toxicity of daily oral cyclophosphamide is considerable and the decision to initiate therapy must carefully balance risk versus potential benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A follow-up study reported 24 month outcomes for 93 of the 109 patients who completed one year of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/24\">",
"     24",
"    </a>",
"    ]. Of the 48 patients who had received cyclophosphamide, 12 also received low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . The beneficial effects of cyclophosphamide on forced vital capacity (FVC) appeared to persist for six months after stopping the drug. However, by 24 months the improvement in FVC was no longer present, suggesting that the response to cyclophosphamide is not durable. Improvement in respiratory symptoms, as well as in skin induration, persisted in the cyclophosphamide-treated group at 24 months.",
"   </p>",
"   <p>",
"    Details of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dosing are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H20#H20\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Use of daily oral cyclophosphamide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intravenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    used in combination with low dose glucocorticoid at preventing deterioration of lung function in patients with SSc-associated ILD has been studied in small observational studies and one randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/15,25-29\">",
"     15,25-29",
"    </a>",
"    ]. In the trial, 45 patients were randomly assigned to receive six monthly infusions of cyclophosphamide plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (20 mg on alternate days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/15\">",
"     15",
"    </a>",
"    ]. At 12 months, there was a modest improvement of FVC in the cyclophosphamide group after adjustment for baseline FVC, but this improvement did not achieve statistical significance. Neither DLCO nor measures of dyspnea showed improvement in either group.",
"   </p>",
"   <p>",
"    Selection of the initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for intravenous infusion is based upon estimated body surface area (BSA) expressed in square meters (m",
"    <sup>",
"     2",
"    </sup>",
"    ) and is adjusted for advanced age, obesity, and renal function. Subsequent doses are based on the white blood cell nadir and response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, these randomized clinical trials suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus low-dose glucocorticoid imparts modest benefit in SSc patients with early-stage symptomatic lung involvement. The improvements with oral administration of cyclophosphamide achieved statistical significance, whereas intravenous administration in a smaller trial did not. However, the intravenous route results in a lower cumulative dose and may be associated with a lower rate of side effects. Therefore, we generally prefer intravenous cyclophosphamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adjuvant glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of adjuvant glucocorticoids used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is uncertain. In studies evaluating the efficacy of cyclophosphamide versus placebo in SSc-associated ILD, many patients have also received low dose glucocorticoid [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. It is for this reason that we usually use a low dose glucocorticoid (equivalent of &le;10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) with cyclophosphamide.",
"   </p>",
"   <p>",
"    We avoid combining high dose glucocorticoids with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    because of the lack of clinical trial data and the attendant risks of scleroderma renal crisis and immunosuppression. One observational series described a short-term benefit to high dose compared with low dose glucocorticoids in patients receiving cyclophosphamide for SSc-related ILD, but this has not been our experience [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressed patients are at increased risk for Pneumocystis jirovecii (PCP, previously called Pneumocystis carinii) infection; thus, we recommend that patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    also receive prophylaxis against Pneumocystis jirovecii. In our practice, we administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (160",
"    <span class=\"nowrap\">",
"     mg/800",
"    </span>",
"    mg) three times per week. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Monitoring therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    has the potential for short and long term toxicity, including neutropenia, opportunistic infections, cystitis, bladder cancer, infertility, and adverse drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/31\">",
"     31",
"    </a>",
"    ]. White blood cell count, renal function, and urinalysis should be monitored during cyclophosphamide therapy. A detailed discussion about potential side effects and monitoring during cyclophosphamide therapy is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H24#H24\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is an alternative immunosuppressive agent for SSc patients with early stage ILD who are not candidates for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or who decline cyclophosphamide. It is generally administered at a dose of 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day to a maximum of 150",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    A",
"    retrospective analysis described 11 patients with SSc-associated ILD who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for worsening pulmonary symptoms or declining lung function. The results showed that among the eight patients who received treatment for a minimum of 12 months, five patients had &gt;10 percent improvement of FVC and three patients remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/32\">",
"     32",
"    </a>",
"    ]. Three patients discontinued azathioprine due to adverse effects within the first six months of therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    appears less efficacious in SSc-associated ILD than oral daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/33\">",
"     33",
"    </a>",
"    ]. In an unblinded trial, 60 patients with early diffuse SSc and ILD were randomly assigned to receive either cyclophosphamide (up to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or azathioprine (2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). During the first six months of therapy, patients in both groups also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which was subsequently tapered. After 18 months, FVC and diffusion capacity were stable in patients treated with cyclophosphamide, but had declined in patients treated with azathioprine. Leukopenia was more frequent in the cyclophosphamide group.",
"   </p>",
"   <p>",
"    Preliminary data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may have a role as maintenance therapy in patients who have completed a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . A retrospective series of 20 patients with SSc-associated ILD found stabilization or improvement in pulmonary function tests after a combination of six months of monthly intravenous cyclophosphamide followed by 18 months of azathioprine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring for adverse effects during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    therapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Dosing and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids, either as monotherapy or in combination with other drugs, have been widely used to treat SSc-associated ILD with variable benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/34-41\">",
"     34-41",
"    </a>",
"    ]. Given the lack of convincing benefit and the increased risk for scleroderma renal crisis, glucocorticoid monotherapy is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link&amp;anchor=H6#H6\">",
"     \"Scleroderma renal crisis\", section on 'Risk factors'",
"    </a>",
"    .) We generally administer glucocorticoids in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adjuvant glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    has been used to treat both SSc and localized forms of scleroderma with modest improvement in skin involvement; however, a beneficial effect on lung involvement has not been demonstrated. Because methotrexate has been associated with the development of pneumonitis and, rarely, pulmonary fibrosis, we do not recommend its use in the treatment of SSc-associated ILD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H387483\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is an inhibitor of lymphocyte proliferation that may prove to be effective for the treatment of SSc-associated ILD. The role of MMF in SSc-ILD has been assessed in retrospective reviews and prospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/42-48\">",
"     42-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23849?source=see_link&amp;anchor=H7#H7\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\", section on 'Other immunosuppressive agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two retrospective reviews of a combined total of 30 patients with scleroderma ILD, MMF treatment for up to 24 months was associated with improved or stable pulmonary function relative to baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational cohort study, 13 patients with early SSc received anti-thymocyte globulin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      for five days, followed by MMF (up to 2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      maintenance therapy for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/42\">",
"       42",
"      </a>",
"      ]. Long-term MMF was well tolerated. Although the extent of skin involvement improved, there was no change in mean forced vital capacity or diffusion capacity.",
"     </li>",
"     <li>",
"      In a prospective observational study, 14 consecutive patients with SSc-ILD were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      sodium (MS) for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/45\">",
"       45",
"      </a>",
"      ]. Six patients showed a pulmonary improvement defined as an increase of more than 10 percent in FVC, and 5 out of 14 patients remained stable. In contrast, the median FVC had declined over the 12 months prior to MS treatment.",
"     </li>",
"     <li>",
"      Among 10 patients with SSc-ILD treated with MMF for 12 months, FVC improved, while DLCO did not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger, randomized investigations are needed before implementing MMF in the routine treatment of SSc-ILD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other agents and ineffective treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs that were previously used for treating SSc-associated ILD produced no improvement in lung function. Ineffective drugs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , para-aminobenzoic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , disodium EDTA, methysergide, and relaxin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/38,51-53\">",
"     38,51-53",
"    </a>",
"    ]. D-Penicillamine, an immunomodulatory agent that inhibits the formation of collagen crosslinks, has been used for over four decades to treat SSc, but its efficacy remains uncertain. Several retrospective studies demonstrated clinical benefits, including an improved skin score, less new organ involvement, and improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. However, in a trial that randomly assigned 134 patients with diffuse SSc to receive either standard dose (750 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or low dose (125 mg every other day) D-penicillamine, there was no difference in the extent of skin involvement or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up of patients receiving drug therapy for systemic sclerosis (SSc)-associated interstitial lung disease (ILD) requires that the response to therapy be evaluated and the duration of therapy determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Assessing response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing the response to therapy is challenging because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement tends to be slow",
"     </li>",
"     <li>",
"      Small changes in symptoms, lung function,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiographic appearance can be masked by the effect of existing fibrosis",
"     </li>",
"     <li>",
"      Stabilization, rather than improvement, may be the best result that can be achieved",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimal follow-up has not been established. We initially evaluate our patients at least monthly for adverse effects of therapy. In the absence of adverse sequelae, we continue therapy for at least six months and then reassess the patient's symptoms, subjective exercise tolerance, pulmonary function, and high resolution computed tomography (HRCT). Therapy is continued if there has been improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is unknown. We generally do not continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    beyond six to twelve months, because of toxicity. Other therapies are typically continued until clinical improvement reaches a plateau, at which time gradual withdrawal of therapy can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LUNG TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation may be an option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is not responsive to pharmacologic interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carefully selected SSc patients undergoing lung transplantation have the same morbidity and mortality of lung transplantation as patients undergoing lung transplantation for idiopathic pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. This was illustrated in a retrospective review of the result of lung transplantation in nine patients with SSc-associated ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/58\">",
"     58",
"    </a>",
"    ]. None of the patients had cutaneous ulcers, recurrent episodes of aspiration, renal failure, or left ventricular dysfunction. Four year survival was approximately 70 percent.",
"   </p>",
"   <p>",
"    A subsequent retrospective survey of 47 patients with SSc (mean age 46 years) who underwent lung transplantation determined that single lung transplantation was more common than double lung transplantation (57 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/59\">",
"     59",
"    </a>",
"    ]. Fifteen percent of the patients died within 30 days following transplant. Late mortality was most commonly due to infection; other causes included respiratory failure, malignancy, and pulmonary hypertension. The one- and three-year survival rates were 68 and 46 percent, respectively, which did not differ from patients who received lung transplants for other conditions. In a separate single center study, among 15 carefully selected patients without symptomatic gastroesophageal reflux or delayed gastric emptying, the one year survival was 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/61\">",
"     61",
"    </a>",
"    ]. All but one of the patients received bilateral lung transplants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) should receive the same supportive therapies used for the management of other types of ILD. These measures include supplemental oxygen, yearly influenza vaccination, periodic pneumococcal vaccinations, and pulmonary rehabilitation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other potential therapies for SSc-ILD are under investigation, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, hematopoietic cell transplantation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Information about clinical trials for patients with SSc-associated lung disease is available at:",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/home\">",
"     file://www.clinicaltrials.gov/ct2/home",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy followed by hematopoietic stem cell infusion has been used in some patients with severe SSc. As an example, in an open-label trial, 19 patients with diffuse cutaneous SSc (dcSSc) and lung involvement were randomly assigned to nonmyeloablative autologous hematopoietic stem cell transplantation (HSCT), or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    <span class=\"nowrap\">",
"     once/month",
"    </span>",
"    for six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/62\">",
"     62",
"    </a>",
"    ]. HSCT was performed after conditioning with cyclophosphamide, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . Improvement in the combined endpoints of a decrease in the Rodnan skin score and an increase in the forced vital capacity (FVC) of &gt;10 percent at one year was significantly more likely among patients who received HSCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23849?source=see_link&amp;anchor=H8#H8\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\", section on 'Autologous stem cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional randomized trials of autologous and allogeneic hematopoietic cell transplantation in SSc are underway. In the meantime, given the high cost and morbidity of hematopoietic cell transplantation, these procedures are best performed in the context of clinical trials (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/home\">",
"     file://www.clinicaltrials.gov/ct2/home",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    mesylate, an inhibitor of the c-abl protein tyrosine kinase, is highly effective for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. It has anti-fibrotic activity in cultured fibroblasts and prevents experimental fibrosis in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/63\">",
"     63",
"    </a>",
"    ]. The selective inhibition of tyrosine kinase by imatinib interferes with the signaling of both platelet-derived growth factor (PDGF) and transforming growth factor (TGF)-beta, two pivotal mediators of the fibrotic process in SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibroblasts explanted and cultured from lesional skin and bronchial tissue from patients with SSc were stimulated with TGF-beta and PDGF, then exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. This treatment led to the inhibition of Type I collagen production in a dose-dependent manner.",
"   </p>",
"   <p>",
"    Two small, open-label, studies of the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate in SSc-associated ILD have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In one study of twenty-four patients, forced vital capacity (FVC) showed a 6.4 percent predicted improvement, and the diffusing capacity remained stable during the one year treatment period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/69\">",
"     69",
"    </a>",
"    ]. In a second, open-label study of twelve patients with SSc-associated ILD (FVC &lt;85% predicted or dyspnea and presence of ground-glass opacification on HRCT), a trend toward improved FVC was seen that was not significant after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/68\">",
"     68",
"    </a>",
"    ]. Adverse effects occurred frequently in both studies; in the second study, 7 of 20 participants discontinued therapy due to adverse effects that were attributed to the high dose of imatinib. Additional studies of imatinib in the treatment of SSc-associated ILD are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a monoclonal antibody that targets CD20-positive B lymphocytes, leading in most patients to long-lived depletion of circulating B cells. The potential efficacy of rituximab for SSc-ILD was examined in a randomized trial that compared rituximab plus \"standard therapy\" (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ) with standard therapy alone in patients with SSc-related ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/70\">",
"     70",
"    </a>",
"    ]. The eight patients in the rituximab group had significantly better forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) at one year than the six patients receiving standard therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, observational studies have reported conflicting results. One series of 15 patients found no improvement in skin disease and no change in pulmonary function tests six months after two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/71\">",
"     71",
"    </a>",
"    ]. A separate series of eight patients with severe and progressive interstitial lung disease noted an improvement in pulmonary function among seven patients and stability in another over 9 to 12 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/19/7482/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the treatment of ILD associated with SSc will require further study in a larger trial of longer duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42029151\">",
"    <span class=\"h2\">",
"     Tadalafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    is a phosphodiesterase-5 inhibitor that has been used in the treatment of refractory Raynaud phenomenon and is being evaluated for a possible role in SSc-lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link&amp;anchor=H782103#H782103\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\", section on 'Phosphodiesterase type 5 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial lung disease (ILD) predicts poor outcome in patients with systemic sclerosis (SSc). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The purpose of treating patients with SSc-associated ILD is to reduce alveolar and interstitial inflammation, in the hope that less interstitial fibrosis will develop. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of patients with SSc-associated ILD includes high resolution computed tomography (HRCT) and pulmonary function testing, including diffusion capacity (DLCO). These tests are used to determine the extent and severity of disease. Worsening pulmonary function demonstrated by serial testing may be the best indicator of progressive impairment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Active disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoalveolar lavage may be useful for ruling out infection, and for assessing the severity of lung involvement, but appears to have little utility in predicting progression or response to therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Active disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical benefits of therapy appear to be modest and associated with substantial toxicity; therefore, the decision to initiate therapy must be made on a case-by-case basis after carefully balancing risk versus potential benefit and the importance of each to the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with intravenous monthly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy plus low dose glucocorticoids (equivalent of &le;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) instead of other immunosuppressive agents for patients with SSc-associated ILD who have respiratory symptoms, abnormal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      declining pulmonary function, and no contraindications to immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selection of the initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for intravenous infusion is based upon estimated body surface area (BSA) expressed in square meters (m",
"      <sup>",
"       2",
"      </sup>",
"      ) and is adjusted for advanced age, obesity, and renal function. Subsequent doses are based on the white blood cell nadir and response to therapy. White blood cell count, renal function, and urinalysis should be monitored during cyclophosphamide therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A randomized, controlled trial has shown that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      is inferior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . We suggest azathioprine plus glucocorticoids for patients with contraindications to cyclophosphamide or who decline cyclophosphamide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Azathioprine is typically administered at a dose of 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day to a maximum of 150",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Azathioprine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend prophylaxis against Pneumocystis jirovecii (previously called Pneumocystis carinii) for patients receiving immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In our practice, we administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (160",
"      <span class=\"nowrap\">",
"       mg/800",
"      </span>",
"      mg) three times per week. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that immunosuppressive therapy be continued for at least six months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Changes in the patient's symptoms, subjective exercise tolerance, pulmonary function, and HRCT should then be assessed. Therapy should be continued only if there has been improvement. Typically, therapy is continued until the improvement reaches a plateau or for a maximum of 12 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , at which time gradual withdrawal of therapy can be considered. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Assessing response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose disease is refractory to the above measures or who prefer to explore experimental modalities for SSc-associated lung disease (eg, hematopoietic cell transplantation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      ), information about clinical trials is available at:",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/home\">",
"       file://www.clinicaltrials.gov/ct2/home",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Investigational approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selected SSc patients who have severe ILD that is unresponsive to therapy may be referred for lung transplantation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Lung transplantation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"       \"Lung transplantation: General guidelines for recipient selection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/1\">",
"      Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/2\">",
"      King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005; 172:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/3\">",
"      Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/4\">",
"      Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/5\">",
"      Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/6\">",
"      Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/7\">",
"      Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005; 17:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/8\">",
"      Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/9\">",
"      Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/10\">",
"      Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/11\">",
"      Harrison NK, Glanville AR, Strickland B, et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989; 83:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/12\">",
"      Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/13\">",
"      Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/14\">",
"      Steen VD, Lanz JK Jr, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/15\">",
"      Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/16\">",
"      Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10:R124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/17\">",
"      Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/18\">",
"      Johnson MA, Kwan S, Snell NJ, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/19\">",
"      White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/20\">",
"      Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009; 136:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/21\">",
"      Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/22\">",
"      Khanna D, Yan X, Tashkin DP, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007; 56:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/23\">",
"      Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006; 354:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/24\">",
"      Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/25\">",
"      V&aacute;rai G, Earle L, Jimenez SA, et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/26\">",
"      Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/27\">",
"      Air&ograve; P, Danieli E, Parrinello G, et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/28\">",
"      Tzelepis GE, Plastiras SC, Karadimitrakis SP, Vlachoyiannopoulos PG. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease. Clin Exp Rheumatol 2007; 25:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/29\">",
"      B&eacute;rezn&eacute; A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/30\">",
"      Pakas I, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/31\">",
"      Furst DE, Tseng CH, Clements PJ, et al. Adverse events during the Scleroderma Lung Study. Am J Med 2011; 124:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/32\">",
"      Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/33\">",
"      Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/34\">",
"      HUGHES DT, LEE FI. Lung function in patients with systemic sclerosis. Thorax 1963; 18:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/35\">",
"      Kallenberg CG, Jansen HM, Elema JD, The TH. Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest 1984; 86:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/36\">",
"      NICE CM Jr, MENON AN, RIGLER LG. Pulmonary manifestations in collagen diseases. Am J Roentgenol Radium Ther Nucl Med 1959; 81:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/37\">",
"      Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/38\">",
"      ASHBA JK, GHANEM MH. THE LUNGS IN SYSTEMIC SCLEROSIS. Dis Chest 1965; 47:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/39\">",
"      Rossi GA, Bitterman PB, Rennard SI, et al. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 1985; 131:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/40\">",
"      SULLIVAN MA, MILLER DK. Pulmonary manifestations in collagen disease. Arch Intern Med 1962; 110:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/41\">",
"      Dines DE. Pulmonary disease of vascular origin. Dis Chest 1968; 54:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/42\">",
"      Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/43\">",
"      Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/44\">",
"      Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/45\">",
"      Sime&oacute;n-Aznar CP, Fonollosa-Pl&aacute; V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011; 30:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/46\">",
"      Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/47\">",
"      Koutroumpas A, Ziogas A, Alexiou I, et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/48\">",
"      Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/49\">",
"      Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/50\">",
"      Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008; 133:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/51\">",
"      Guttadauria M, Diamond H, Kaplan D. Colchicine in the treatment of scleroderma. J Rheumatol 1977; 4:272.",
"     </a>",
"    </li>",
"    <li>",
"     Sackner MA. Scleroderma. In: Modern Medical Monographs, Grune and Stratton, New York 1966. Vol 26, p.76.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/53\">",
"      CONNER PK, BASHOUR FA. Cardiopulmonary changes in scleroderma. A physiologic study. Am Heart J 1961; 61:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/54\">",
"      Steen VD, Owens GR, Redmond C, et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/55\">",
"      B&ouml;ni A, Pavelka K, Kludas M. [Treatment of progressive scleroderma with D-penicillamine (Metalcaptase)]. Munch Med Wochenschr 1969; 111:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/56\">",
"      de Clerck LS, Dequeker J, Francx L, Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum 1987; 30:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/57\">",
"      Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/58\">",
"      Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000; 5:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/59\">",
"      Massad MG, Powell CR, Kpodonu J, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005; 29:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/60\">",
"      Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54:3954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/61\">",
"      Saggar R, Khanna D, Furst DE, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010; 36:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/62\">",
"      Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/63\">",
"      Bargagli E, Galeazzi M, Bellisai F, et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008; 75:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/64\">",
"      Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/65\">",
"      Rosenbloom J, Jim&eacute;nez SA. Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum 2008; 58:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/66\">",
"      Distler JH, J&uuml;ngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/67\">",
"      van Daele PL, Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008; 58:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/68\">",
"      Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63:3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/69\">",
"      Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/70\">",
"      Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/71\">",
"      Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/19/7482/abstract/72\">",
"      Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40:641.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4375 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7482=[""].join("\n");
var outline_f7_19_7482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Active disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Oral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intravenous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adjuvant glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Monitoring therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H387483\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other agents and ineffective treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Assessing response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LUNG TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INVESTIGATIONAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42029151\">",
"      Tadalafil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4375|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/35/35381\" title=\"diagnostic image 1\">",
"      HRCT ground glass in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35382?source=related_link\">",
"      Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23849?source=related_link\">",
"      Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_19_7483="Social benefits thal Greece";
var content_f7_19_7483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Social benefits provided to thalassemic patients in Greece",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Free medical care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cash benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tax allowances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Entry to universities and other institutions of higher education without examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paid training and technical education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work incentives (large industries are obliged to employ disabled people up to 4 percent of their labor force)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early retirement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facilities (eg, transportation, electricity, telephone)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Politis, C. The psychosocial impact of chronic illness. Cooley's anemia, Seventh Symposium. Ann N Y Acad Sci 1998; 850:349.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7483=[""].join("\n");
var outline_f7_19_7483=null;
var title_f7_19_7484="Classification of osteochondritis dissecans";
var content_f7_19_7484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of osteochondritis dissecans",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"5%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"31%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnetic resonance imaging findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arthroscopic findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td>",
"        Depressed osteochondral fragment",
"       </td>",
"       <td>",
"        Articular cartilage thickening and low signal changes",
"       </td>",
"       <td>",
"        Irregular and softened articular cartilage with no fragment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td>",
"        Osteochondral fragment attached by an osseous bridge",
"       </td>",
"       <td>",
"        Articular cartilage breached, low signal rim behind fragment representing fibrous attachment",
"       </td>",
"       <td>",
"        Articular cartilage breached with definable fragment that is not displaceable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td>",
"        Detached, nondisplaced fragment",
"       </td>",
"       <td>",
"        Articular cartilage breached, high signal changes behind fragment indicating synovial fluid between fragment and subchondral bone",
"       </td>",
"       <td>",
"        Articular cartilage breached with definable fragment that is displaceable but attached by overlying articular cartilage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td>",
"        Displaced fragment",
"       </td>",
"       <td>",
"        Loose foreign body",
"       </td>",
"       <td>",
"        Loose foreign body",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        DeLee JC, Drez Jr D, Miller MD. DeLee &amp; Drez's Orthopaedic Sports Medicine Principles and Practice, 2nd, Elsevier Science, Philadelphia 2003.",
"       </li>",
"       <li>",
"        Dipaola JD, Nelson DW, Colville MR. Characterizing osteochondral lesions by magnetic resonance imaging. Arthroscopy 1991; 7:101.",
"       </li>",
"       <li>",
"        Guhl JF. Arthroscopic treatment of osteochondritis dissecans. Clin Orthop Relat Res 1982; :65.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7484=[""].join("\n");
var outline_f7_19_7484=null;
var title_f7_19_7485="Erosions and ulcers";
var content_f7_19_7485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of erosions and ulcers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Mouth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aphthae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Avitaminosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Burn",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epidermolysis bullosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema multiforme",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hand-foot-mouth disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpangina",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen planus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pemphigus vulgaris",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Perl&egrave;che",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic epidermal necrolysis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Balanitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chancroid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diaper dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema multiforme",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fixed drug eruption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fungal infections (tinea cruris)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intertrigo",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen planus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen sclerosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphogranuloma venereum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Squamous cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Basal cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bullous pemphigoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Echthyma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema multiforme",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ischemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Necrobiosis lipoidica",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pemphigus vulgaris",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Porphyria cutanea tarda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyoderma gangrenosum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spider bite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Squamous cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stasis ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic epidermal necrosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7485=[""].join("\n");
var outline_f7_19_7485=null;
var title_f7_19_7486="Contents: Pediatric resuscitation";
var content_f7_19_7486=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric resuscitation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric resuscitation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/17/28948\">",
"           Assessment of perfusion in pediatric resuscitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29030\">",
"           Basic airway management in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7864\">",
"           Basic life support in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44328\">",
"           Carbon dioxide monitoring (capnography)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/24/27014\">",
"           Continuous oxygen delivery systems for infants, children, and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/48/29450\">",
"           Emergent endotracheal intubation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/16/20746\">",
"           Guidelines for pediatric advanced life support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/59/41912\">",
"           Hypovolemic shock in children: Initial evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/51/22327\">",
"           Initial assessment and stabilization of children with respiratory or circulatory compromise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14104\">",
"           Initial evaluation of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/8/26762\">",
"           Initial management of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26346\">",
"           Neonatal resuscitation in the delivery room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42901\">",
"           Physiology and classification of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15738\">",
"           Primary drugs in pediatric resuscitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24026\">",
"           Rapid sequence intubation (RSI) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13354\">",
"           Septic shock: Ongoing management after resuscitation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/33/4634\">",
"           Septic shock: Rapid recognition and initial resuscitation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10346\">",
"           Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15481\">",
"           The difficult pediatric airway",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8057\">",
"           Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-7C502250C1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f7_19_7486=[""].join("\n");
var outline_f7_19_7486=null;
var title_f7_19_7487="Lung thallium unstable AP";
var content_f7_19_7487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Increased lung uptake of thallium during perfusion imaging predicts future cardiac events",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 431px; background-image: url(data:image/gif;base64,R0lGODlhAAKvAdUAAP///4CAgAAAAP+AgIiIiICZzEBAQMDAwAAzmf8AAMDN5kBms/9AQHBwcDAwMP/AwKCgoBAQECAgINDQ0ODg4PDw8LCwsFBQUJCQkP+goP8gIGBgYCBNpv9QUP9wcP8QEHCNxv9gYODm87DA3zBZrBBAn2CAv6Cz2dDZ7P+wsP/Q0P8wMP/w8P+QkP/g4FBzufDz+ZCm00hISISEhEhVbr8MJk1NTTA/X0BQb9+2w8TExL98lm9Mhb9shi8pfK9gfyH5BAAAAAAALAAAAAAAAq8BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t5IHAbu8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1da/B4UBBtfd3t/g4eLj5OXm58bc2gG47e6Mu+vv8/SD8YT39fr7ePmC/vwCCmwDEFDBgQgTijnoh6HChxCvOOQzMaLFi0wq6tGIsaNHAByjqAPQ4EKYkB9TPkTZhEIACdwCODBwkp3KmylZMjkgoKdP/5tfdOIcSk+okgoHHGw4cGDCQqBEoyo0ymQC06Y1pWpNSFVJA58CaILpurVsK7JIBETgBSGr2bdFoWqRIHdsXbh4aaE90sDAVad28wq2tdeIAbBig94dzHhV4SIQerUN3BiiiweYH8BRwSADkQwMVHhh4IEJaQAeGADg7JnK4yJIY7utrHBAgtsJ4DxIMICIbc1YdvcGkED1kuIAGOR2MQD4lNdDIPRM2mA27YS7jWcYkKJDB9EAMnQgzWK7ixYuwjNg0EJIagYhwLdY7yH9g/EeWABgEYJBB96+JaDZAK0RCACB84Wg34GkGThECMX1VlyC+t23XnvEqaYcAMxptv+dEB8+wJ13LAzQGRHQCSGBAxLokpgXKV63SnZCKKfBCglocGACHQygwQPKfSCgBwl48F97GgzgwQc6QujBACs8kAKPRHYAAI4eQDicEL9lKARyt62gQQIhoMajbcYJgaMGqoU5ZpkDhGBiAp4ht6FwyeWW544f4NinkOkJEaMAB/jVl3UyCkTjnlfmxqQQLLCg3IJMDoAmAA+kJiQA//Wo2X+WjqkCmZgCOESXyHmJHAtg6ujlEHh6yapqLLTQAY4SapgbnhvuiapqXQq6mBUSbOBAABFUR1miAy3a64ap1qgncUlamsGUHaSA434h4JhACspZaimesXIp4KtgGpf/7pdpljpcqsit8EELLQBo564APpvbrzs6F6MFPkVAAaLM6nNeAlEyuuGR9wE5LagPbGcbd2MCEEILmSZAL49SKshkxlv2C4CQWa7rJY4pZBBtqdmi2+aPROa6J56dLrnvucgFC9KwVkwQAAYDJ1FBZAEEDYAFPxudRIwFl2Ibbgrnxp+QGrjQK7dCfjAAC2tWPEDWpR04Jo/hCRlugB5+8AGRbaqrmgpjKtdunh+4HN5tZ9/r7mpj3nqzZjmfK6wXFzgAAAVrLR3wwF85EIHASzDd9ORESClikXUMaoEQhyJxwMAXCBBABWoBgIEAyi7NM+WsV6FyAh8omPnqUwiw/zlJLyKxgQAQ8EST70To4stIrRdPSYwXJPsVBktMIIDhwAM/hPC9EG/89Y/EOIEEPTlQgRIQROA9AM4bDrBJSkiOPS2nsSI5VkqcnmwAbXFvQeiTqb7+QysX0T8qMTJA7pBwGJ/QZAIOUEvq9Le/W3SIQ81hTgpSk4K7JckFLugPebykAu5wqD/xGUWMtlEG9TXQEuTizW6ShCMVEOkDoQFSnEhVHBb0iQUu6NPX6iaKGH1FgAZYYBdMeEJKpLA5AJqSzEDUn3Qx4AOiqZeclOOcTwQQMQQr4iuOeMRXEckDNLrNmAZEJnEFChREfIoWaTEqrYVrNyF4QAup9QCrff9LZW1awag0wIJRrSAFmQIPGmknhQr0ZQIXuJ1i1kgLImlASyuEXYFuowIVmG1dtrGStsJ0RisSMgqhI9QG0LdIRuKiXPMYFAb8QsJlmbIWqHyH5vxiAFLC6JOvzCUbYrSBx3Evf7fUpTDtEKMKhC5ZahymMuOQxiwu85ln0F4CkelMaFozmVzgngESiEspNPOacshMC8RFznKa85zoTKc618nOdrrznfA8ZxWHoDkhXGCAW/gmOJ8gsXiaU4PeQth65OTPghr0oAhNKDznObghTiYAG6jmPsFQHnRqoFoJxRhmynJFsISllBMVQwos1Sl0tqaBPgQiEIWoBX3mRUT/5MyMTDEjSCpM6UkZWJAwXTrEbu4vh0+y1HvWQ9T1jA03SGVTUYsaVBOF7Zk85UJUzbKCp1ZBBTOVaTkZulOf0mGqW/HACkJKBrBmwaxEmeAHOklWkHqBAkoLZi5F9EWutlWqXn2C77LhVkaayIN3HYP6KrANATBProxRwTgVyoCQBVaiVYjNAb4X15bm1SPdUVuPFNqcx5b1suCbjgNYmk/Q8kOx6YxZTT1LEdMiYUUtamVfLdLPDmhWnRVkrUFcewRCGQqflu1ICi4qrhasVreIiFGxjkXN2SKEBZfDEHIh8a/FQfYdKhgpA+IWgtxOl7q8PYLPgIZNfTygiWzi/85xv5u98BahAZPBgHuPgFZKaACMOmWvJaCDFKUw5Z7XrUUGXKXfTECHJx6NqCvpoYGTFvgS0HEJTHaBge8t2BZaDQGBmaUABcAAADBQgAi8AIIFFKHEXkDBAk6whBMsAAUAWAAIAOBiGAt2vkOYQGWdS4rLYKa2RBVSmIj6JLtWBgEIeAEAFICAAnhhAQgoApS1UAAEKGDJTV5Cla+MABMroAAjvrEXELnSAE9CYkMNKAzXs1kCZYatxkOylZnsZADEYAEvGIEQCnACFDj5BAUYgYxhYIIXC6HECzABjKdMhCl/ecSPFkGgS1xnFLzgBQUA8xBEAGUTnIDJIKC0EP9cjGc9bxkAXV4ymCV9ZVbTONCDLrSNoxCjBBrQzI8oD3HHlRlrIoAEJeDACLIMAgSA4AUI0DMCSoDkGCOAAxxYNpQ5IAQOFAAEwXa2lKN86i0zucvMPoEISlCCAkD5ykJAQbRJAIJvLyDcAHgBCAoQbUlbGdUm9naW6exsaEv72c/BsRB4JwAAbEDgKEJ4H+7DIwdPtMsn6HKWS0ACECcZ1RUXgqOzzGgFlJjZ2m40t++tbycPO9MIYPGph3Bqfp8cAJJeQLS/fO9UlxzLTt54zqPsTYQTqkWd4/Ek4pRfsqYayllONb6XrvEo83vKw84zCaLM6CFMudtz3neTsY7/7j3fm990HjcJTmACK5/a5ll38tOdznGe0xrhdNmdAGzZ00xo17FG9zKSnYzsEVQ5BkzX9toBUOVARzvkVo9yDH5N77TjPOoKODcRCt9hrReAyS+IvNlrnm8ro2DZ5m47zhEPBe1NwJgXsLDQH3HTzj5W6WV3MgyQXYIZB17n2obB1P1N+txDmQTIrrzaib3sqXcd5tHOvOUBUHaKb57Lnb9ysTkQe8GLvudegAAwcZ0IDUj3wXWIgQJGMPUP2wPhAP5sJGAqLg2DHw/R/rWe8YFwCLSIKYBZ/SH6s9X386OjPQFcZ6VwcsAARuZ/cZF9ksF9gZAAcIaAUCBjZ0GA/yVEgW/gAtMCgUigdEfAgapQX1YAgmAAJODnaqwmaSNQYnoWcdYmAiJQaIO2dH6mZy+YaLM2SPKQCP1kKfABfmDXZExmbVOHAsVWAi8WeQVQdiaAbzBAcTAgdgVAbiJkgWJ2CAOGUeJygJ71g5eXZS/HgWQHZSbWZe8GY4tnAqF3fJ4QQDZREgw4BzB1UQ6HgFzIhUxXbO2Wakg2c4SHAGiYaWGGg1sgYTExE28oB381hxD4eeUGZV1oAgowhKjGASIGZSMQcWNIAp/HATDweSQwAh53g2uIYwgGFhQoglNgKRqIBNMXe0G4bCzWhwiAAijAbGK4dFWmZOSHZCQQiP+exAX9tRTwc2F+0GCr2AT8Vg9MYxX41zx8JQRIQ16RQ4VgMGDHiIxZpowI9xW3hgQUED4FxznP8zg7lnCDYIzXCBEKIH474wVqwRaK0xNCQDoRYDqoM418sINxsmHpGBAKYAJTRwKQ2I5dQBdPII8AED0flT7UaAXDhYXj0o+tgAIxkGkdpgCiOARflmkcaW6ZVwQp9RdLgJAK+SLUwwvWUwdT8n0SiQowAGgc+QLkhmmIJnNyxgELkJOI1pEcqYYEyQUFFIAjGY7lczRzFzy/kJJzkEFW1ZKggAIXGZNJ1pExkJFFAJUdZpFOECNEswvbRwQUgGCfAwD2gz/4SAf/mSIvHaCFThkIL8mTcJlpNRl/z5aTMpZpJ2B+FfgFkqV6RhAApkg+00RaINmQTLAdtlVVbNmWf/CSyIZpcQmXF2mVu1R/okWYA+gGupYkGfCAjOmW41cAj5mXhqBcLOIih5gF4tFwn/kHF9lhFXltCzB1vyZjpJlcPlcoBxB0iHUGDyCHRdeaYrCRkcmRMJiTtClnJGCXicaRoKiX8AB3xoIsmIkFURUCZSKcZnACO1mcmSZ+rymIXAAwPQE5xDgGBqidYsCd9GZtlycLy5g05WUGDqieVXCRscmT0HZtsagXCIcBijSfZICB9rkE65iEyKmcOfmHHQkC/XkLVyQB/w1QjsGFBiRYoEXwjwGJhuDpkwKhPQ1gawqmf10ALtn5XcTpnSoKl3jmoRHBNENzGAJonYYJAPUCRsv0mjqaonGZkyv6ozzpoi+6jT5xAc/Ym1HAfu10Ud5FGyHmdzzJnFKKdHJWpbU5pTqpokIqIwHkABDglySaBH/lToqIFx43m7x4lx0JijvaYdBJVsVkBl2hiq2Tojn5nOkoTT93WGGKBHSKF+z5oz7aky1Za4+zmzMqEaD1p2ZxAvsJpO/5mbOEmufZBIyaECIAk2yKkUowAtD2oBiKBDESAatkAcWSmgeCd/zgccAGmcxJl1eKZ+a2hKGaEQgHmD5xpHXXBP+oRU6NNRAKIJPstqUaeZEwSay1+pNcsEqJJKBFIB631X+uIAKhCamZlmi+mKx9egcO8Zvet16mEGKwea3vJm0LYK2Eqq3O2hDDEien8GU1yWxIZpd/CIrZqq6zk4NHcCKMQK1Qiq4d6aMXea/4+gcxEpYAIBuVmp6G8GU5yWxGeK4AG6QFmwi1ZhIVcKqV+iOHUGj2WrGlMCh8JVtISgQZGAiSRnHICrKbMKqHdQF0h1dJcLJ+8I9+uLIs27IItzsOkEBfWVpI8JuBEInlRrA520MIVwG701w8dqF+8IK0erSpgIoBhwSg0QesWgIfKbVTi3BkJkDVqahHAC6qOgf/wUpx7ca17oNwtiaUF6YyOHoHUImtausKgyIdBneKcjElZdoGZxptOJm2dTuB7ngAQJeoISgXSqIGFOmdOcmpgxsLygVRPRGzQDsEKtAjZQADfjdtDBqZOBu5Ieu1pwezYCqz96FZi3mfJhBt5zoCbyq6slSjwTQA35EFUOm4L0CZsptKOOZbWBQYl+oEuVtigKumoNu7AwEdBjABfVFmwlu2RjAChXa88wa5yvsRVIt9w2sEnGZt2Ju9Q8G8KgW2WdG9QwADhRe74osT0OFRbrtI6AsAnroARtu+N6FcfHVw51u2hGZ7+LsVqsQ5iFsF8TC8KGACKhvAHIVwMppA/yMaTB3gYORXAorGwGZRTKGUelnBsACAbbeJwQ08ZvmnRukpAiTQiyIMFwFUwDRKHCwwArW3wnjxL4ajfrkRajRcww4cvIrBKtg2fzucwduoUmGbuDngAyo8xG+xvbSGAyXAA0zMw2N2T+Y7FjfwA1YyxU3Mtj58S/PLxe7rc3jLv3axUWI8wl3wc4iKqmm8EnBHuUfpBENDP6dLX7T7xv5Jwqh3x0iQQIdxw2epx1rBX2N5OJPlBOcDAKEToKKax4QsuTh2OoDhPHwaOaIDEpk8yJFMFMwryABgiE0AmOxAyrbayVLxyUQgykxwOtWxPEVwkrsgQOhQy7Z8y7icy/+6vMu8LA1KaQW7c1inE8FKQAEC0CLcE1ey3MvM3MzO/MzQHM3SDAy6egWI41ElvAT2d8w/i8qvhEjdU83ePM7kvD51/KVbMAHyhc4JGxnsjAV1bBPn7MdQUMeKNM9aMIwUIF8VNgTRSKFHMIxXwRT+LJ9TMIx13M/QaNBPsM8/45fDeDQM3RL87JdWYTT/LAUO3c9IMdAWltFToM52PI/urHog7QQizc4pbdITXRXrrHrxXNDS+AeA/DxbELw1DcpVMAEREBYSIAQ5fQUVkEAJpCxBfQU+s5AAEJQ33Djk2ARJnRgeJY6OY55PENXzWNMR8D1ObdVNwNRCgNVU/dT/TgDWYd3TbTiOXv3VPgE9HpUNXQ3QSYDTYWHTJKHWck0EwRu8cX2Q3cjTPj3Wa60Hi9zIWtAWxlxwhW07WMA9+bfYjhwFrkyWAkABkH0FBZQYFlABGUso9GiPR7zU8TsdBP3Zkw0FmS0EPGE4hzFZpXPaiszZ3JMNqZ2wr32Psd3ZfGVr7GDauP0Em63bHS0dle3boW0EiC2PkG3cT5Dc4ejctl2PsM0E0E3Z+cfcDZHJppzPX1HK2r3JO33M3GMSprzdrnGPrV3e4F0F0kMEyVySTtDeAWikCflR7a1XCznUz3Oq8C0FyazaC9nfUPDf1JnJAh4F/y0EuxNRBw4F/7v53d4dAA2+BA8OFBVe37+j1E1w4c4jAeON4SCe3RG+BRBwGNWh3q612knBOyhuBYltAD2tCxCOBfcN2iBe40nQ3hdAuQIz4TuR373EPd7j40sA29JD5Ekw2c6DNAZu3xr+BLCd2AOD5Nps4poc4VSO3FYuBCV+j1kOGVau4j775XMw2bAMlIRi5oaF1B9Fymp+ySFNP9xj42duBff9FQpWlIu84U8u2k1h03vu4At5OuwQOgGg53P8BHgePAuJ6JabBIuuyabo6FIQ6QouAHkO6Ik+Ba395pQuEoRCBK396ahNKM5DE6RM6nxgzMhc2VmQFAHAjXB1zIbr6ldgP/8J9Dm0nuBV0DuhUx2sXut53Tyn4wCJHDp0IeGUfT+8A9XFPlmwvrTfU5bNDgXq/DyTJR3G7rPLbpZPgOy7kA3XbuzTbjve3gTgLuFheQALPjDU3s1JkO7ZgGBG8+5SAOuyHuz/be8bfiyyju894e7mXu074e8Bv+y53u0E3wfbLAHwHgUUYGsScDsN//BXPU2TUfFY0BMGyeXc4/BYEJSh7lHsgEAKVNZg8Tm25gCVPJhSIPJw3dMdb/JM2wQkL9q5Kpgn79c/QU+bTPPHrdeBueVh7fIaLfEU//GTAfQNjfSH4/Q6X/PFDPU0v/RGX85Yn/Vav/Vc3/Ve//VgH/b/Yj/2ZF/2Zn/2aJ/2ar/2VDDQCyFAWDABBmDxJT4Bct8WvMn2qwAWEWDxVCAdO84TPnUYAL46gMkUmRwZV9DnSUD4ej8I8hjxoV7itbQ5SDMwkcHZzwsVFLABYFsBFHAYS7E76kBYlX84Em4B+VPrEs4TDdAXbShAG+AUhy/4AKD4LpENuQ8SkTH3iMTB0XHMRXP7AnRYE+D5F9A73KPsjw8ICAn4jNwAL1HZ0sE8EfDTErAWDfDT08MNC749zwMBCQQTobwWCWQVaqHU4Dj3CAbjzU4XDXD9moz47ED4tm/73SPzEEwEXwEEEcOkIWhcBBiKwBHYXCARgQECsF6x/1ntltv1fsFh8ZhcNp/RafWa3Xa/rQKB9TAFUAIGieBQiTgskgAiIjYCKLIgNgzsAvgA6gIAJqacBALqGrQY6S4BAiUPGgykABwPIgE4U1MbH+2wYCMkAhyHBCQaMCpU5+B+gYOFh4mLjY+RzeSsIAQ2KP4UHzeYBHgnLvYiEK2KGuoMTB9ZK2tRPbM4IT0jAy8sHOZOU1fZPV0PAGCvYHFrA6pYIMWkVzKDBxEmVLiQIUI5B6Jsq3PhAKN8dQRcsEKlooAJVxhZaBbu1Lp3gyJAOIBBJTosISeQq3XJwh5x5yRxohQhzz2Sr8LFknCAAhJMEDBtsHCAUC8LHxtGlf86lWpVq7/kyLkAldqfRwD2WLCCBFeVKxOkMPqZr1eESWQlLHV5xYIUDDIrxJNgc54ndUUkUJOET1/QK448VtgghSeFeEw+1hV0lXJly5cxU66AK3Nnz59BhxY9GgCGuaRRp1a9mnVr169hx5Y9m3Zt27dx59a9m3dv37+BBxc+nHhx48eRJ1e+nHlz58+hR5c+nXp169exZ9e+nXt379/Bhxc/nnx58+fRp1e/nn179+/hx5c/n359+/fx59e/n39///8BDFDAAQks0MADEUxQwQUZbNDBByGMUMIJKazQwgsxzFDD1ibgpsMNQWTPAElMMSzEE8ebgBQJDCDFRBT/YfQOo6wiECvGG79rwCwcefwuJlSg6lFI64rI6sUhkXxOAJ5q2THJJ5ujxRgdZvjHyiuxzFLLLbns0ssvwQxTzDHJLNPMM9FMU8012WzTzTe1ZOuXUVA5IMhfCJABzj357NPPPwENVNBBCS30yxGDYcRIYQggAMpHkaklGKT+cRKORiHNlBhJg7HgkADuvNRRTUn9hdM5H7pgA0ZHLdVVNk6FoxAHDsiD1VdxVSPWN/gw4IBFbs1V2DJ2dcMAByRAAoNgh20WjGLbQEsOB3gJBlNnse0CWjfsJObabMHFYts1LnDgDp6YDTfccdUQwMZR0lU3W3bTcLebI934Vt55/0n85YIIGihiWWtb3RdbetGYYA8mqgVGX4ObRTiNbr+ogFJuPglACS8ehlhYic1oUQzElkSkCAcIwViLjj3GFWRi8d2CKACM2swt0zThguWWXX2ZjCJaNCDnL6hpKRxw6MBShoJ5drlfOBSVI2YsKDEXaaQhUZrppnt+WqEoqJ2EIHe62JnrTH0eY4J4DpBgYC5MAxggsNxFwlIszD770bTFQDkCUabuZdG1lxx6i7z1fpLvMNz11VaCE391cTAiwMCAmlaFPPJSJ/+C5K8c3npzKDv/wvKT4h2ddK/fqIDi1FVPsvQumpm2YTxFj33I2bmYJYAiMg9dd0h53+Lve/9hH77H4rX4HZUnXn8DceVhZD6drBbFnXrFWW+DUivvZmP67UO0HqHxyd/Q/IPQTz/D9Q1q3/0L4U9G/vkrrP8sCG4XFX8e9dcJnvSvDff7n4QCmDREae+AMUpgMQzYwAfVLwrZE54EUVS/tLTIcP7D4Ik02EHNfRBE9WtA8IYRQRIqaH3YsyADV6ih9QWNhiLMV+5iOKH6fWgSKvNgDjFUvwU+7oJApF/31KCiWbRICMkzIoTWNyM51MiJT3SQCcMHQyvqEIls+FH0frhFBHZRDUWSWhXFyEIypkEIl8gFGtOIoPrxwRoB0MgI4zjBNaKhceUKnBpUmMf+mDAAgRD/QBbFh0NBHiiBEwhVGBe5oB2yzW1wjKSA6uc3wFnykgCao0Bq9cc0BLKTYXDBA1D5gKiogAEZwEIGGKACYDDAA2CgJQA8wAAAsNKVZtCg5TDHyVKeYQAJMGYCovKABAwAC8VUJRuUyUwAJECXX6AmABiATBcM4JnE2uMZPicnLQ7zF8qsZgYGkIIOdECWAMhAB2jJAnS6oAUucCcDGNACK+SSASFoZwvw6QF7PgCeHmABAFgQAgZ0YJnNTIAqB9DLiAIgogANwUEpSsuJXiEE1GQmNS16UILiU5/T1GU2AbBNVaLTCix9QDrXyYIBtNIK+judjfBITjiY0wrZ1MAK/xKgAYomoAMD0MADsvmBh3ogAR5gqD41MAAPfECoHfXAAFbwgBQQlakdAABQPdBRaVrBmSa1wjWNuQINJCAEuCRqMatpBaBqQJdpXWtbBxCCmSbAlddEaTSxiczADvUDQC2sUu35QG8pUqdp4Olgv4pMqlqBBSzIJkapOgC4AuABuVQqABhaVFUyVLNrVQFbOdvQK5T1mma9JgvQKlSzXgGwZoWtLlnQgg4A9aMnRSZgUTpY1uqyrC104T7G2dg2PDa4KG1tTwU7zahqNgNb7UAKgIrQEAA1ASnIpmY1C9jakvWhs0VrNc971rimVpqtveYKPtCCFjTUr79taHOROf/coapyhqRwABNRCEnlroGeCcgqZFH6VIIiNbqkfQA6i5nOtQIgBC3obALkS1StXpSqFx7rfgGg1LCm16xATUEGnpva65q3rkdlam8HC9jQTjW/5b1mcb9phuMB4ITCHDAYinlMBCMzoUrVgAuCq12lfmAALJjrhAew5FpSdK1EdadSv+vQlX7gA0ytK3p1qYK1ZnO9gf0Ai91pzCzXl727XOtua6zKG5d3jquqwAVEiQZS/rg2Wn1pU6liQuzl2Ax75vNsUJyAD1w00IQug+UM8LYiHvo/ik0hYyltH0v7ONPCuGVzNp3TTgcjxVkodXJCPelRk0GlKeXmNlOQyxT/pDmqLnCBQuNpVhWkM6UK9SdxhJjnNRj60OJdpjKjClQVMPUDsURqXlFLTRYUlgUuKGyUzzyc+hExDDHBgqc2VjZMr3oLxuZmQ7cK45Yq9LwM+IAs56vXbHYTOIIOmg2vQIEKXuFkKRM3uc1gbnPPlqke4Kkx1wpRtoLXnsIRIvYCRzIr2Kw0Rvg3wMlwWiZ/V5kheICypfsAJHcXxXVdwWk1wILTriAFnW1ncFLdhWWs42iwqNWVlobxMjBVA2JFtqIlakwVqADL6S2mV7Gb1obD3NFkuCnjfHE1m2tN52oYb3cEnRWcytwXVftERi5e9TNcnTtzlMSdA0cBjMws/yx2C7vY6fNJ5Glr0JOIB8A4Nm64p6d+SDjWZFS9d/jU786Fu7Tg4970qhAb8dqJuYAbz57HS0/vkR/P5G9o+cEr/gsQwYLnRa06eYKX9KU3/elRn3rVr571rXf962Efe9nPnptbWF8AaFUnYIVeXqdMgepDS3vhD5/4xTf+8ZFP78Nw3gufOyPvUfR74+NzyfhUfQYw2hkFKAAGAICBAkQADBAsIAvjBwYKFnCCL5xgASgAwAJAAAD2u38YtxdC0FjE6QiNXqpNNX7Ll+41EAABXgAAFAABCgAYFgABsmAB3aAAEEABDBABvwACJRAByE8BCiD86o/5tMVEuA3y9P9D+pBPs4JPs2bNOQYwAg8wAQEgBhbgBUbACgrgBFAgAU+gAEYA/mDABNrPCsZvAUzA/RwQCxxQA8MPCUVAB8fPBVHgBV6gADbwCkRgAU3gBA4QBJrQCtgvBmfQAgEAAw1wA5dQAstQ/nSQB32Q/sYA8wqo8uJjvq6qBCMq+6IDAUigBDhgBCgQBBAABF4AAWYQAUpgAN8PATiAAwhxATnACjigAEBADw+xARkQDC3wADGwEE9ABEqgBApgASXQClBAEUkABDBxATQRAF4ABApAEZcwAsOQ/C6RAlvwEBNxERHRm37h5sBH/9gjAzRAA1JwPjDwBDCQAkuABLyPAMP/UBmt4AgpsAgVYPwKcRKNsBJhcRYTkA+lEAHUDwyvAAxrkRsBYAkXQBE1EBbFUBsnMAGh0R0ZkAxu77iErdDgEDxIMPWCsZfqQwwXkALFMBYF8hkZsBYdkA9lkAQYsAivwAEtkQVpEQEfMhRpEBZrsQU5kQROwAQiEAzXESIT0CALMhrjsQ09EG6kplJ8kTtQbA5Tjx/tQwwxMQEDcQQgMAYGchJFEgAgUAcV0RobkgFjAA9bESTbESEVABSxoCe3LyIL4ABfICk7Uh1lMQJRgBA/kSTbEShH5iS54FdwQdIC7zwygKlgUkACkiMTEAYCsQTiLyffcRJhQCFvkSvl/3IBSSAQmzIk+5AQFZIiy1ERo9IpAYAjk3EqL7AqJdAPOUAtdVIr5dEruaACTMMXVpI6IMyoomoYISYGFGAEFLL7QmN9KKABCGEDHkkEtyMzgxG8ztJjFBEPZ1A05pEJ7u0yg+OUVK81qUvzbE8ys8D5kEs1cyMfWY/dqEmvUO81fTM4gVMhGI805BD2RA5b4M853DCReuOlNJMz1SUgtwA8lyM7h+0eWSOXNupVzrAMl3AExm8GjfERRUAEfJAHBfIGZ5A+hZANmQ41otMzUMw7XeUiEfAAH1EhUcAPS6D9krIAONIEYhEGkhEGMrIAOhHYnpMfIEKccFM05os5S/+FQJ+SAskRPDdyAckPA1HR/YbSBLISMH+jhXBvA+okNd/wNiAsGAX0VURURAfSD01RDAcQHXkSAVxUCjmwP6GGHjsUM4BxukD0Va7SExdwRE1AARA0DDkA/BZwBIwxRUngKjkABq6SBEZgGvnTKrZv+6SwTd30TeE0TmG0pjJ04jCARVQS+lTjSaN0WBhTLQ2UENWvSBEABVCgEFFUICGwAEFzAEkgSRNCAz9xASh1BfGQUuEvTjV1U6VwTk2hTs/Ch/R0NFSgBfbxbGoxUjl1VTeVUnVwTUXTIGzKAFBnVD2jVDuAyzqgT/clVZNh+7qQVYX1TT31ILJODraOODH/A1d1tQVeTm9EYE23zybf1DOldfvKQAMpNTY5wFWLVTXMDgDQrkmTgf9y9QM6wFkbJFqv9TOH9V3hdVIxFRUtdRHndQHgtD7nVSHr9VLv9UgpFQu/FTbkjsfqsQz+c6dagPROUF33Q1Kl8F4xtRD7dUElFl/jNWM59UylFVJ/oV0VIAbadGBlo++mIB7EkvIMgjtVb7sMTDmpyw7R4/tENl5dVQo59lo9VnZAdeKQAO/IVQyIziVRz8LgAwVs8hwx8EjjlWQ1hTwByTzRwMk+jD6i1UEZEV9HIE03B2pHSWrPYJ3qQwF8cACF0DNjlXq8Vs/AtgywSmaF4wRYUWPp/9ZNKRX8Gmhtz0CFMpP1pupZh8MY57ZuCddplYfwRgEbklVlM85Up8v1lK82IJZTS9HyTJYPnoCT3klXeTU0JpdwIxZjV9VwV22OLCeUqog7g9FhP0NuWfVmQXdkm9NzelYfQIlWq2gF9Kpzr+IEEnFYSXd226B+FmMWDsmJHiDbPuNqE3FQhbcqCO9n8e1GuUCvruJaa7ZsMfAFnPd5obd2eYiHxjKlEiAAjUFS9XUB+HUFSWBemRZvvdcyhIhEQpBxtSCvkuH7XgBfrXVN45c11keJWMRFkucDIhcOkPYTFVEIg/d/QSOKXIiKQi8DVmANUOBa27Rsu1UHudaBX/8Di4yBZdKVC1w3CDE1NlewW+d1btHWg3NDf77IRrVTC95NC3z3ETtVWjvYhR2uds1oOO33CoguC264e3kYO2u3jQLgjURtALyKC5v3iKdjjuqgAuwoXjKgBnYgB6NYiqe4dvvovxiFBiaVWykVBIzYi6GDkAwJkbbAYgCCgLKAAMgYC3uAr9Q4OxppAuS4C+KBEcwl764gA3g3j5kDflynWizgjsKAbJBg63ixFmTABhqlki35kjE5kzV5kzm5kz35k0E5lEV5lEm5lE35lFE5lVV5lVm5lV35lRulSvIAVKFhSUQBiOlOEhzhaSI5AGYAloE5mIV5mIm5mI35mJH/OZmVuZNlGRN+wTQGYkncODg9YZcNWY7CIRAcQFS9AGd4DPCumUCW2BKaZAyWYCj2gJvDudKYdAwgYA8kYJrXeT96eW7mGWLgmH/eYAIwII4nDin0uQ3gmETyuY/JAI5xqqC5JUgooJ93gS40Rp2/MkjqBBUgOtzM4HXg+KGtANwkmgsaWmNuJ3o8mgxCmqOtICYwpqTL4KR5wXUqWpEjOmH6OaAVuqNnWm1qulr42Z9xGqO7baevYKAv+qMp448Jwg0gzgqQOpDXQFr0gKmnIKnTIC+qIWea2otsASSyIpD7bRu6bavjAHu6gQn8jQwmQKytmhEigBe+2qivZ1pS/1qsv9lv4Jqr5TqlpYBE3roMosZqXCgf+loZsier6/qsoe75lvqwwVoMFhuqJaCs7fozHNlevOcOlqGyF9cM9iBINFsNvDmdP1sNFMUwLKACKmAP+mBJKm56X+L59IEPLJrivJkMSrsTzMUiaNvixuC0U/sRbltcWbu2Gxm1VVuqPWG3XXsLfFu1Ybp2KEC5z6AKlmAONFu6xYC6Z0675wC7w4C7raCzh3q4ebszrNmauaUIdLmaT8MMKGEvwO6821seLc4i5FsysQYL0lnqhC2/pYYiaC7AywBrrBpZVoW/zyCdOyEoELwMFDwAAMYeau5g9VsAMIYaDtwO8nvA1f9bHNYbEzQcl7vglvuFxAN8w8HAxN97DzSiwc2bvTMUAhhBE+57DeqAVuIBKWBcDap7IGplx218OL3ZxTtvHy7AEiQixClcwBXDeKmFyMWAuLEGysHAmynBUyRcwB+tvKsbEag8u2fcwz38y2knzJkhzMmcC2Tc4m78AHI8za/CmwXmFyxCzsH5DCjhJzTG4uY8iQDCJuw8ZTMauYAnpccG7MIAxXvBTg6dkccAa0xDEozC68jmZ5zh82CB0hFdDApdHAZN0x2d0y/9CjDc0M2l0tGgzvk8CUA9ZEBn0Vvdr/kgzz081jvjnNvGwtvAzX9HDigA1xV8DcKCbYBd19X/QCWQQBOK/a69gJ+ZoA9oxh+cue2OFwycnVZcpwm6gheoXZ6z4Nr7oBlw/Hi7nQyQgBacGdy5vW6qPQzO3RzUDiyfgW4Wud3F4N2dGSMwptwHvAmK5NdxIdcRgd9T3N99ndf/nd7dLtENXteH/REIvjPeuSzcwDHkIC6YAZ693drvziwmPp7Z4OL75eM33gui5hXqjnCAFgxOnigewwGgQuWXewtansekQErszvDIwIVyAnvyQeZ3vu5qCh2Avgx4vhcMp+hb+jEwHgBIPqXvbubzjenFwuJxwUaUHgysvulV3iyy/p7BPuzFfuzJvuzN/uzRPu3Vfu3Zvu3d/u3h/z7uVaOiN0VknpoKvkDGHQnv4UXuawN7UmJSMgLEm04dUqH5ZNsTkGINRJzmLdPvj2EZLD4fZJxWxcJTEAEpUHsUFsgKKGARhKYCKIARaJQaEMWKLf8OMEEkriDXMSETRoGvWwQ1byIVFh8P8gH3TQEpqAAbLuB2moEWMr9FBmYCFgEKXJ9DIV8YthvsLqABltjCm2FZZgEseKIBIrv1RwTDFYYJIEAvwgFlcM8j6iAtrqCCOEJqpKAKaME0I7sven4dQuEezBoX4gGFikAIiMAIlAUIKAJHYHOBRAQGCKDpfEKj0im1ar1is9ott+v9gsPiMblsbgoEzYMSQAkYJP+CQyXisAgwgEhkE6BAQWwYtAXMAbAFAEwoFQkEsDVEEa49AuApHjQYJAEYHiQCUIaGFh62PaFGSAQYGjBKNGBUiKqd3eLm6u7y9vr+AnelNUEIbFDYCR5uDAnQTlzIRQA2NQg0sBl4HpI2toJaQlEiWibiXVg4qH2GjpZbmh4AoDqhCrC2MllwDtUG/wMMKHAgwYIB0xxAMo3NhQOE5LERcKHJEocCJjghZKGYtk/k0O2JAOEAhpHhnmic0K3VIwtytoFTRIlRBDjwOp7SlkrCAQoXHiWEtMHCAT61LGA0qHQp06ZOn95Kk+ZCUmZ2DgGQY6HJz3tMnExIQginvFp0ERZ1lUD0pBMLSTCsrKBOwkt2lsZZk8BMUbx5Op0YulhhQ5KaFNQNweg2D9TGjh9Djuy4wj3Jli9jzqx5M2cAGNh2Di16NOnSpk+jTq16NevWrl/Dji17Nu3atm/jzq17N+/evn8DDy58OPHixo8jT648WBAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 1271 patients with unstable angina or non-Q wave infarction entered into the TIMI-IIIB trial, 277 patients had increased lung uptake of thallium during stress imaging. Compared to the 1044 patients without lung uptake of thallium, those with increased lung uptake had a higher cardiac event rate (p = 0.001) (upper panel) and a trend towards a higher incidence of myocardial infarction and death (p = 0.09) (bottom panel) at one year.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jain D, Thompson B, Wackers FJT, et al. for the TIMI-IIIB Study Investigators, J Am Coll Cardiol 1997; 30:421.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_19_7487=[""].join("\n");
var outline_f7_19_7487=null;
